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2Abstract
The p38 mitogen-activated protein kinase (MAPK) pathway, like the c-Jun N-terminal
kinase (JNK) MAPK pathway, is activated in response to cellular stress and
inflammation and is involved in many fundamental biological processes. MAPKAP
kinase 5 (MK5) is one of several kinases that are regulated through direct
phosphorylation by p38 MAPK. To study the role of the p38 MAPK pathway, and the
function of MK5 in vivo, we have generated mice with a germline mutation of the MK5
gene. The mice have been characterised by Southern blot analysis, RT-PCR,
sequencing, as well as Western blot analysis and protein kinase assays, which all
demonstrated that the targeted disruption of the MK5 gene resulted in a null allele.
MK5-deficient mice were viable and fertile. The intrinsic MK5 kinase activity is absent
in MK5-deficient mice and could be detected in wt mice, but we were not able to
activate this kinase with typical p38 pathway stimuli in our experiments. After
immunization, the gene targeted mice form abnormal large germinal centres. Most
cytokines are normal in the MK5-deficient mice. In resting cells GFP-MK5 is located in
nucleus. Treatment with arsenite results in nuclear export of MK5 after 90 min in the
Hela cells only in the case of co-transfection with p38. Participation of MK5 in MAP
kinase signalling pathways and its functional significance have been discussed.
Keywords: MAPKAP-Kinase 5/ p38-MAPK/ deficient mice
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3Zusammenfassung
Die p38 Mitogen-aktivierte- Proteinkinase (MAPK)- Kaskade, wie z.B. die c-Jun-N-
terminale- Kinase(JNK)-MAPK-Kaskade, wird als Antwort auf zellulären Stress und
Entzündungen aktiviert  und spielt eine große Rolle in grundlegenden biologischen
Prozessen. MAPKAP-Kinase 5 (MK5) ist eine von verschiedenen Kinasen, welche
durch eine direkte Phosphorylierung durch die p38-MAPK reguliert wird. Um die Rolle
der p38-MAPK-Kaskade und die Funktion der MK5 in vivo zu untersuchen,
konstruierten wir Mäuse mit einer Keimbahnmutation des MK5-Gens. Die Mäuse
wurden durch Southern-Blot-Analyse, RT-PCR, Sequenzierung, Western-Blot-Analyse
und Proteinkinase-Assays charakterisiert, welche alle zeigten, dass die gezielte
Zerstörung des MK5-Gens zu einem Null-Allel führte.
Die MK5-defizienten Mäuse waren lebensfähig und fruchtbar. Die intrinsische MK5-
Kinaseaktivität fehlte bei den MK5-defizienten Tieren und konnte bei den WT-Mäusen
nachgewiesen werden, allerdings konnten wir keine weitere MK5-Aktivierung mit den
typischen Stimuli der p38-Kinasekaskade erzielen. Nach der Immunisierung zeigten die
genveränderten Mäuse abnormal vergrößerte Keimzentren. In unstimulierten Zellen ist
GFP-MK5 im Kern lokalisiert. Die Stimulierung mit Arsenit führt nur im Fall einer
Cotransfektion mit p38 zu einem Kernexport der MK5 nach 90 Minuten in Hela Zellen.
Die Beteiligung der MK5 in MAP-Kinase-Signalkaskaden und ihre funktionelle
Bedeutung werden diskutiert.
Schlüsselwörter: MAPKAP-Kinase 5/ p38-MAPK/ defizienten Mäuse
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ATF activating transcriptional factor
AP-1 activating protein 1
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BMK 1 big MAP kinase1
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CDD common docking domain
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eIF-4E eukaryotic initiation factor 4E
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ERKs extracellular signal-related kinases
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FGF fibroblast growth factor
FMLP fMet-Leu-Phe
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GADD153 growth arrest DNA damage 153
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GFP green fluorescent protein
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HSP heat shock protein
IE gene immediate-early gene
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LSP 1 Lymphocyte-specific protein 1
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macrophage-activating lipopeptide-2
MAPK mitogen-activated protein kinase
MAPKAPK(or MK) MAP kinase-activated protein kinase
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MEKK mitogen-activated protein kinase kinase kinase
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MNK1 MAPK interaction protein kinase 1
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PP2C a serine/threonine protein phosphatase type 2C
PRAK p38-regulated/activated kinase
PTPase protein tyrosine phosphatase
SaOS2 osteoblastic cells
SAPKs stress-activated protein kinases
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THP-1 human monocyte
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TNFR tumor necrosis factor receptor
UV ultraviolet
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VEGF vascular endothelial growth factor
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I.  Introduction: p38 MAPK Cascade: Pathway, Regulation and Their Functions
1. MAPKs
1.1 MAPKs
Mitogen-activated protein kinases (MAPKs) are evolutionary conserved enzymes that
connect cell-surface receptors to critical regulatory targets within cells. The MAPK
pathways convert receptor signals into various outputs. In mammalian cells, four distinct
MAPKs have been identified:
(1) extracellular signal-related kinases (ERK)-1/2
(2) c-jun N-terminal kinases or stress-activated protein kinases (JNK1/2/3, or SAPKs)
(3) p38 MAPKs (p38 a/b/g/d)
(4) ERK5 or big MAP kinase 1 (BMK 1)
MAPK cascades are composed of three tiers of sequentially activating protein kinases,
which commonly are referred to as MAPK, MAPK kinase (MKK) and MAPKK kinase
(MKKK). An activated MKKK phosphorylates and activates a specific MKK, which in
turn activates a specific MAPK:
MAPKKK MAPKK MAPK
(MKKK or MEKK) (MKK or MEK)
MAPKs are activated through phosphorylation on both threonine and tyrosine residues
at the Thr-Xaa-Tyr (TXY) dual phosphorylation motif. This motif is located between the
subdomains VII and VIII of the kinase catalytic domain (Hanks et al., 1995) and confers
specificity to each MAPK subgroup, allowing for their independent regulation.
For ERK, JNK and p38 MAPKs, X = Glu (E), Pro (P), and Gly (G) respectively.
TEY for ERKs
TPY for JNKs
TGY for p38 MAPKs
These dual specificity kinases are relatively specific for each MAPK subgroup, allowing
for their independent regulation.
Normaly MAPKs are activated by specific MKKs (MAPKKs), but there is some cross-
talk between the different cascades:
MKK1/2 (or MEK1/2) for ERK1/2
MKK4/7 (JNKK1/2) for the JNKs
MEK5 for ERK5
MKK3/6 for the p38 MAPKs
Each MKK, however, can be activated by more than one MKKK, thus increasing the
complexity and diversity of MAPK signal transduction.
1.2  General Functions
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Each MAPK recognizes a number of substrates allowing the regulation of many
processes. Hence, once activated, MAPKs need to find the correct target. The ERK1/2
signal pathway is the main signal transduction pathway, mostly activated by growth-
related stimuli (Cobb et al., 1991; Sugden et al., 1997). The JNKs are activated in
response to a number of cellular stresses, such as high osmolarity and oxidation (Ip et
al., 1998). The ERK5 signal pathway regulates serum-induced early gene expression
(Kato et al., 1997). Finally the p38 MAPKs are involved in immune responses and
inflammation, cell growth, differentiation and apoptosis. The actual roles of each MAPK
cascade are highly cell type and context dependent.
In order to learn more about MAPKs functions, it is very important to investigate the
normal and pathophysiological functions in the whole organism. In recent years, with
the analysis of the mutant mouse strains produced by gene targeting, we have gained
new understanding about the functions of MAPK. Transgenic mice have been produced
with various deficiencies in MAPK signal cascades particularly at the MAPKK and
MAPK level.  Chang et al. have summarized the phenotypes of MAPKK and MAPK
knockout (ko) mice (table 1-1). What has been learnt from MAPKK and MAPK gene
targeting is summarized below.
Table 1-1: Phenotypes of MAPKK and MAPK ko mice (from (Chang et al., 2001),
extended)
_________________________________________________________________________
MKK/MAPK Phenotypes    Similar to
_________________________________________________________________________
MEK1 defective placental vasculaization    ERK2?
(Giroux et al., 1999)
MKK4 defective liver development    c-Jun knockout
(Ganiatsas et al., 1998)    (Hilberg et al., 1993)
MKK7 embryonic lethality of unknown cause
(Dong et al., 2000)
MKK3 defective IL-12 production
(Lu et al., 1999)
SEK1(MKK4) defective proliferation and IL-2 production
in peripheral T Cells
(Nishina et al., 1997)
_________________________________________________________________________
ERK1 defective T-cell development    MEK1 dn negative
(positive selection) (Pages et al., 1999)    transgenics
JNK1 defective T-cell differentiation to Th2 cells
(Dong et al., 1998)
JNK2 defective T-cell differentiation to Th1 cells
(Yang et al., 1998)
JNK1 or JNK2 defective T-cell proliferation and IL-2    JNK1 dn negative
Production (Sabapathy et al., 1999)       transgenics MKK4 ko
JNK1 or JNK2 defective activation induced death    JNK1 dn negative
of thymocytes (Sabapathy et al., 1999)    transgenics
JNK1 & JNK2 IL-2 overproduction (Dong et al., 2000)    MKK7 ko
JNK1 & JNK2 neural tube disclosure (Kuan et al., 1999)
(Sabapathy et al., 1999b)
JNK3 resistance to excitotoxic neuroal cell death    c-JunA63/73 knockin
(Yang et al., 1997)    (Behrens et al., 1999)
p38a placental defect (trophoblast cells)
(Adams et al., 2000)
p38a insufficient production of erythropoietein
(Tamura et al., 2000)
_________________________________________________________________________
dn=dominant-negative; ko=knockout
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1.3 Gene Targeting in p38 MAPKs Cascade
(1)   p38 MAPKs
Within the p38 MAPK subfamily, only p38a has been inactivated by gene targeting.
This resulted in embryonic lethality. In an inbred C57BL6/J background, p38a
deficiency resulted in lethality before day 11 of gestation, owing to defective placental
development (Adams et al., 2000). When the placental defect was rescued by
aggregation of tetraploid (p38a +/+) and diploid (p38a -/-) morulae, p38a -/- embryos
developed to term and were normal in appearance. This indicated that the defect was
secondary to insufficient oxygen and nutrient transfer across the placenta (Adams et al.,
2000).
A role for p38a in various aspects of cardiogenesis including the regulation of
cardiomyocyte differentiation, apoptosis, and hypertrophy has also been suggested
(Clerk et al., 1998; Wang et al., 1998 ; Kolodziejczyk et al., 1999; Davidson and
Morange, 2000). However, Adams et al. did not detect any obvious changes in
differentiation, proliferation, and apoptosis of cardiomyocytes in the different
embryonic stages analysed (Adams et al, 2000).
It has also been reported that some p38a -/- embryos die between embryonic days 11.5
and 12.5, and that those developing past this stage have normal morphology but are
anaemic owing to failed definitive erythropoiesis, caused by diminished erythropoietin
(Epo) gene expression (Tamura et al., 2000). It has been suggested that p38 affects Epo
gene expression at the posttranscriptional level, most likely through mRNA
stabilization. This indicates that the p38a plays a critical role linking developmental and
stress-induced erythropoiesis through regulation of Epo expression.
The function of p38 signalling in normal development has also been examined in
Drosophila. A Drosophila p38 MKK gene, licorne (lic), was isolated in yeast (Suzanne
et al., 1999).  It was found that both in yeast and in cell cultures, lic can activate
vertebrate p38 specifically, suggesting that at least some components of the p38
pathway are conserved in Drosophila. In Drosophila, oogenesis provides a workable
genetic model to study pattern formation and the establishment of asymmetry in the egg.
The polarity of the oocyte and the future embryo depends on several cell communication
events between the germ line and the somatic tissues, which signal the specific
localization of few determinants at the anterior [bicoid (bcd)], posterior [oskar (osk)],
and dorsal [gurken (grk)] regions of the developing oocyte (Ray and Schüpbach, 1996).
It has been reported that lic mutations provoke polarity defects in the eggshell and
embryo, as a result of reduced activity of two localized determinants, osk and grk. This
fact indicates that the Drosophila p38 MAPK pathway is essential for oogenesis
(Suzanne et al., 1999).
The p38 MAPK pathway was thought to be mostly involved in inflammation and stress,
but with the analysis of p38a deficient mice and mutations in lic in Drosophila, it has
come to light that p38a additionally has critical developmental functions.
 (2)   MKK3
MKK3 activates p38 MAPKs. MKK3 deficient mice were viable without obvious
abnormalities, but showed an impaired type I cytokine immune response. MKK3 ko
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macrophages were defective in the production of interleukin-12 (IL-12) and interferon-g
(IFN-g) following immunization with protein antigens and also in vitro differentiation of
naive T cells was greatly reduced (Lu et al., 1999). Though this defect occurs at the
transcriptional level, the identity of p38 MAPKs responsive transcription factor is still
not clear (Lu et al., 1999).
(3)   MAPKAPK2 and MAPKAPK5 (MK2 and MK5)
Over the past few years, our laboratory (Prof. Matthias Gaestel’s group) worked on the
downstream targets of p38 MAPKs and successfully produced MAPKAPK2 (MK2),
and MAPKAPK 5 (MK5) ko mice (subject of this work). Currently, double ko mice
(MK2 and MK5) are under construction. We found that MAPKAPK ko mice are viable
and fertile, grow to normal size and do not exhibit obvious behavioural defects. They do
show some defects in the production of some cytokines. The production of tumor
necrosis factor-a (TNF-a) and IFN-g are markedly reduced and the release of IL-1b and
IL-6 are also reduced in MK2 ko mice (Kotlyarov et al., 1999). Under certain
experimental conditions, the production of IL-4 was markedly reduced in MK5 ko mice
- about 75 %  inhibition (details follow in this thesis). These data indicated that different
populations of TH cells could be affected in MAPKAPK ko mice.
(4)   Activating transcriptional factor 2 (ATF-2)
ATF-2 is a substrate of p38 MAPKs (Jiang et al., 1997; Stein et al., 1997; Cuenda et al.,
1997; Goedert et al., 1997). ATF-2 mutant mice had decreased postnatal viability and
growth, with a defect in endochondral ossification at epiphyseal plates. The animals had
ataxic gait, hyperactivity and decreased hearing. In the brain, there were reduced
numbers of cerebellar Purkinje cells, atrophic vestibular sense organs and enlarged
ventricles (Reimold et al., 1996). The widespread abnormalities in ATF-2 mutant mice
demonstrate its absolute requirement for skeletal and central nervous system
development, and for maximal induction of select genes with CRE sites, such as
E-selectin (Reimold et al., 1996). Later experiments with ATF-2 mutant mice also
showed that ATF-2 is critical for the full induction of adhesion molecules (E-selectin, P-
selectin, endothelial adhesion molecule and vascular cell adhesion molecule-1 -VCAM-
1), cytokines (TNF-a, IL-1b and IL-6) and chemokine genes early in an immune
response, but the absence of ATF-2 results in an over-exuberant response after 1–2 days
(Reimold et al., 2001).
(5)   cAMP-responsive element-binding protein (CREB)
Another transcriptional factor, CREB, is a substrate of mitogen- and stress-activated
protein kinase 1 (MSK1), a protein kinase directly downstream-to p38 MAPKs. It has
been shown that CREB a/d-deficient mice (partial mouse knockout for CREB) are
deficient in long-term memory (Bourtchuladze et al., 1994), while the complete CREB
knockout leads to perinatal lethality as well as defects in T cell development (Rudolph et
al., 1998).
(6)   MSK1/2
A mouse embryonic stem (ES) cell line with targeted disruption of the MSK1 gene locus
has been developed. It was shown that mitogen-induced phosphorylation of CREB at
Ser133 was greatly reduced in these ko cells (Arthur and Cohen, 2000). MSK1, MSK2
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and double knockouts (both MSK1 and MSK2) mice were produced recently (Wiggin et
al., 2002). Experiments using embryonic fibroblasts derived from these ko mice showed
that MSK1 and MSK2 are required for the stress-induced phosphorylation of CREB and
ATF1 in primary embryonic fibroblasts. In contrast, mitogen-induced phosphorylation
of CREB and ATF1 was greatly reduced but not completely abolished. The mitogen-and
stress-induced phosphorylation of CREB at Ser133 has been linked to the transcription
of several immediate early genes, including c-fos, junB, and egr1. The ko of both MSK1
and MSK2 resulted in a 50% reduction in c-fos and junB gene transcription in response
to anisomycin or ultraviolet (UV) radiation but only a small reduction in response to
tetradecanoyl phorbol acetate (TPA) or epidermal growth factor (EGF) in fibroblasts.
The transcription of egr1 in response to both mitogenic and stress stimuli, as well as
stress-induced apoptosis, was unaffected in the MSK1/MSK2 double knockout (Wiggin
et al., 2002).
2.  p38 MAPKs
p38 was first isolated as 38-kDa protein, which was rapidly tyrosine phosphorylated in
response to lipopolysaccharide (LPS) stimulation. Molecular cloning of the protein
revealed that it was a MAPK family member (Han et al., 1994).  p38 was identified as
an upstream kinase of MK2 in interleukin-1 (IL-1) or arsenite-stimulated cells (Freshney
et al., 1994; Rouse et al., 1994). Other p38 isoforms were identified (p38 b/g/d) and it
was demonstrated that they share 74%, 60% and 57% amino acid sequence identity with
p38 (now named  p38a) (Jiang et al., 1996; Lechner et al., 1996; Cuenda et al., 1997;
Wang et al., 1997). All of the p38 MAPKs have a 12 amino acid activation loop
comprising the “TGY” motif. They are activated by the phosphorylation on the Thr and
Tyr residues of the TGY motif (Raingeaud et al., 1995; Doza et al., 1995). Like p38a,
p38b is also inhibited by SB203580, but p38g and p38d are not affected by this
compound (Cuenda et al., 1997).
p38a and p38b genes are widely expressed in most tissues (Jiang et al., 1996).
However, p38g and p38d were found to be differentially expressed in the tissues
analysed: p38g was mainly expressed in skeletal muscle (Lechner et al., 1996; Li et al.,
1996) and p38d  in lung, kidney, testis, pancreas and small intestine (Kumar et al.,
1997).
The domains of the kinases which bind the substrates and activators of all the MAPKs
are termed the common docking (CD) domain. This domain varies among the p38
MAPK isoforms. The CD domain motifs are: DPDD for p38a
DPED for p38b/g
DPEE for p38d
However, the CD domain alone does not determine the docking specificity. For this
reason, the concept of a docking groove has been proposed. By inspection of the steric
structure of p38 and ERK2, a groove comprising both the CD domain and the ED
(Glu160 and Asp161 of human p38) or TT (Thr156 and Thr157 of rat ERK2) site have
been identified (Tanoue et al., 2001). The docking groove of p38 and ERK MAPKs may
be utilized for the docking interactions with the MAPK-interacting molecules (MKKs,
MKPs and MAPKAPKs). Each amino acid in both the ED (TT) site and the CD domain
may affect the docking specificity in a distinct way (Tanoue et al., 2001).
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The properties of p38 MAPKs were summarized in table 1-2.
Table 1-2: Properties of p38 group MAP kinase members (Ono et al., 2000)
_____________________________________________________________________________
p38 Other names No. of Size of Apparent Sensitivity to
isoforms Amino acids mRNA(kb) MW(kDa) SB203580
_____________________________________________________________________________
p38a p38, CSBP,SAPK2 360 3,5 38 +
MPK2, RK, Mxi2
p38b p38-2, p38b2 364 2,5 39 +
p38g ERK6, SAPK3 367 2,0 43 -
p38d SAPK4 366 1,8 40 -
_____________________________________________________________________________
3. Regulation of the p38 signalling pathway
3.1  Extracellular Stimuli
p38 MAPKs are activated by extracellular stimuli which include environmental stresses,
pathogens, cytokines, growth factors, and other factors.
3.1.1  Environmental Stresses and Pathogens
p38 MAPKs transduce the signals of environmental and some pathogenic stresses. Table
1-3 summarizes these stimuli.
Pathogens activating p38 MAPKs include macrophage-activating lipopeptide (MALP-2)
and Mycoplasma fermentas lipid-associated membrane proteins (LAMPf). Mycoplasma
fermentans, a human pathogen, is a potent activator of monocytes and macrophages. A
synthetic analog of the Mycoplasma fermentans membrane-associated lipopeptide
macrophage-activating lipopeptide-2 (sMALP-2, 200 nM) can also activate p38 and
other MAPKs. This activation induces mRNA synthesis and protein secretion of IL-
1b and TNF-a in human monocytes/macrophages and the murine macrophage cell line
RAW 264.7. The specific p38 inhibitor SB203580 abrogated both cytokine synthesis
and NF-kB and AP-1 transactivation in response to sMALP-2 (Garcia et al., 1998).
LAMPf, (1 µg/ml) or LPS were also reported to induce IL-8 secretion by THP-1 cells
(human monocytes/macrophages) and human polymorpho- nuclear neutrophil (PMN).
Both ERK1/2 and p38 pathways are involved in IL-8 production. SB203580 efficiently
blocked IL-8 production in both cell types in response to either LAMPf or LPS (Marie
et al., 1999).
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40 J/m2 Raingeaud et al.,
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8,6 J/ m2 Wang et al.,
1997b




















Anisomycin 50 ng/ml Wang et al.,
1997b
Na3VO4 1 mM Wang et al.,
1997b







3.1.2   Cytokines
There are some cytokines which lead to activation of p38 pathway, such as TNF-a, IL-
1/2/7/17/18, TNF-like-1 (TL-1) and granulocyte-macrophage colony-stimulating factor
(GMCSF).
(1) TNF-a and TL1:
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The cytokine TNF-a was found to stimulate the p38 MAPK signalling cascade in
human umbilical vein endothelial cells (HUVEC). TNF-a increased the activity of the
p38 substrate MK 2 and the subsequent phosphorylation of the small heat shock protein
27 (Hsp27) about two to three fold (Pietersma et al., 1997). In osteoblasts, significant
activation of p38 MAPK was observed following treatment with IL-1 and TNF-a and
similar results were obtained using primary bovine chondrocytes and an SV40-
immortalized human chondrocyte cell line (Kumar et al., 2001).
The activation pathway from TNF-a to p38 was demonstrated as follows:  TNF-a  binds
to its type-1 receptor (TNFR1) which recruits TNFR-associated death domain protein
(TRADD). TRADD can also bind two additional signal transducers: TNFR-associated
factor-2 (TRAF2) and receptor interacting protein (RIP). RIP can also bind TRAF2 and,
accordingly, TNF treatment is thought to result in the formation of a
TRADD·RIP·TRAF2 complex . RIP or germinal centre kinase (GCK) can interact with
TRAF2 and then can activate MAPKs via MKK6/p38 or MEKK1/MKK4/JNK
pathways (Yuasa et al., 1998).
TL1 is a member of the TNF cytokine family and it can induce apoptosis in bovine
pulmonary artery endothelial cells (BPAEC). TL1 up-regulated Fas expression in
BPAEC at 8 and 24 h after treatment, and significantly activated JNK and p38 MAPK
(Yue et al., 1999).
(2) Interleukins: IL-1/2/7/17/18
In KB cells, IL-1 can activate p38 MAPK (Freshney et al., 1994). In human neutrophils
the MKK3/6-p38 MAPK cascade is selectively activated by IL-1b (maximal activation
by 300 U/ml after 10 min), and activation of this cascade mediates IL-1b-induced
superoxide release and up-regulation of CD11b and CD15 (Suzuki et al., 2001).
IL-2, and another T cell growth factor, IL-7, activate both JNK and p38 MAPKs in the
murine cytokine-dependent T cell line, CT6 (Crawley et al., 1997). Stimulation of
normal human articular chondrocytes with IL-17 induced nitric oxide (NO) production,
concomitant with an increase in transcripts and de novo translation products of the
inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) genes. The IL-6
gene was also up-regulated. ERK, JNK and p38 MAPK, all respond to the activation of
IL-17 in chondrocytes and the DNA binding activity of NF-kB was also significantly
induced (Shalom-Barak et al., 1998). IL-18 can activate the p38 MAPK pathway in the
chronically infected U1 monocytic cell line. IL-18 increased HIV type 1 (HIV-1) and
IL-8 production and the induction was inhibited by a p38 specific inhibitor (Shapiro et
al., 1998).
(3) granulocyte-macrophage colony-stimulating factor (GM-CSF)
TNF-a and GM-CSF activate ERK and p38 MAPK. Both ERK and p38 MAPK
cascades contribute to the ability of TNF-a and GM-CSF to prime the respiratory burst
response in human polymorphonuclear neutrophils (PMNs) (McLeish et al., 1998).
3.1.3   Growth Factors
The growth factors  involved in the activation of p38a include: transforming growth
factor b (TGFb), colony stimulating factor-1 (CSF-1), erythropoietin (EPO), Steel locus
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factor (SLF), fibroblast growth factor (FGF), insulin-like growth factor I (IGF-I), nerve
growth factor (NGF), platelet-derived growth factor (PDGF) and vascular endothelial
growth factor (VEGF).
(1) TGF-b ( transforming growth factor b)
TGFb-activated kinase (TAK1) is a TGF-activated Ser/Thr kinase, which can activate
p38 MAPK in COS7 cells (Moriguchi et al, 1996). Later, it was found that TAK1
mainly activates JNK in 293 cells. TAK1 is a physiological regulator of the JNK and
p38 MAPK pathways, but not the ERK pathway. It is likely that the induction of
apoptosis by TGF-b is through JNK activation (Wang et al., 1997).
(2) hemopoietic growth factors: colony stimulating factor-1 (CSF-1), Steel locus factor
(SLF) and erythropoietin (Epo)
Activation of p38 MAP kinase is involved not only in responses to stresses, but also in
signalling by growth factors that regulate the normal development and function of cells
of the immune system. The hemopoietic growth factors, including SLF, CSF-1, and IL-
3, activate p38 MAP kinase and its downstream kinase, MK2, in mast cells and
hemopoietic cells (Foltz et al., 1997). This activation occurs through two distinct classes
of receptors. IL-3 acts through a hemopoietin receptor, while CSF-1 and SLF act
through a receptor with intrinsic tyrosine kinase activity. Although IL-4 also acts on a
hemopoietin receptor, it failed to activate p38 MAPK (Foltz et al., 1997).
Another hemopoietic growth factor, Epo, and IL-3 were also reported to activate p38
MAPK and JNK in mouse hematopoietic progenitor cells, but this activation could
proceed through a kinase other than MKK3/6 and MKK4 (Nagata et al., 1997). Epo and
IL-3 normally regulate growth and differentiation of erythroids and hematopoietic
progenitors.
(3) fibroblast growth factor (FGF)
FGF activates p38 MAPK and its substrate in SK-N-MC (fibroblast) cells. Activation of
the p38 pathway by FGF regulates gene expression at a cyclic-AMP response element
(CRE) by stimulating the transcriptional activity of CREB (Tan et al. 1996).
(4) insulin-like growth factor I (IGF-I)
IGF-I binding to its receptor can rescue SH-SY5Y human neuroblastoma cells from high
glucose-mediated programmed cell death (PCD). The high glucose conditions can
stimulate both p38 and JNK tyrosine phosphorylation and nuclear translocation.
Interestingly, IGF-I activated p38 was independent of glucose treatment, while IGF-I
inhibited both glucose-mediated JNK phosphorylation and nuclear translocation. The
activation of p38 and deactivation of JNK by IGF-I may lead to the protection from the
apoptosis (Cheng et al., 1998). IGF-I was also reported to prevent apoptosis by
activating p38 MAPK in pheochromocytoma (PC12) cells (Pugazhenthi et al., 1999).
(5) nerve growth factor (NGF) and NGF withdrawal
It has been reported that NGF withdrawal leads to sustained activation of the JNK and
p38 enzymes and inhibition of ERKs, which are critical for induction of apoptosis in rat
PDF created with FinePrint pdfFactory trial version http://www.fineprint.com
22
PC-12 pheochromocytoma cells (Xia et al., 1995). This indicates that the dynamic
balance between growth factor-activated ERK and stress-activated JNK-p38 pathways
may be important in determining whether a cell survives or undergoes apoptosis. It was
also found that NGF (100 ng/ml) could induce sustained activation of p38 and inhibition
of the p38 pathway blocks cell differentiation in PC12 cells, suggesting that p38 plays
an essential role in neuronal differentiation in PC12 cells (Morooka and Nishida, 1998).
Some scientists reported that activation of the p38 pathway may mediate apoptosis. Both
in Rat-1 fibroblasts and in differentiated PC12 cells, in the presence of NGF, p38
activity and the number of apoptotic cells was very low (approximately 1.0%). After
NGF withdrawal, p38 activity was selectively elevated and apoptosis increased to 15%
(Kummer et al., 1997).
(6) platelet-derived growth factor (PDGF)
Incubation of airway smooth muscle cells with PDGF induces the activation of p38
MAPK (Pyne et al., 1997).
(7) vascular endothelial growth factor (VEGF)
VEGF is a potent chemotactic agent for endothelial cells. In primary cultures of
HUVEC, VEGF can stimulate both the ERK and p38 MAPK pathways. Activation of
the p38 pathway results in actin re-organization and cell migration (Rousseau et al.,
1997).
(8) basic fibroblast factor (bFGF) and forskolin :
It is shown that p38 MAPK and ERK pathways can be strongly activated by bFGF and,
to a lesser extent by forskolin, in murine F9 cells. The activation of MAPKs will later
activate cholecystokinin (CCK) gene promoter (Hansen et al., 1999).
3.1.4 TCR/CD3 complex and the CD28 costimulatory receptor, CD40 and Fas/CD95
p38 MAPK may be fully activated in mouse T cell clones by signalling via either CD3
or CD28, but CD3/CD28 costimulation does not further enhance the amount of p38
MAPK activation (DeSilva et al., 1997). In contrast, stimulation of CD28 fails to
activate p38 MAPK, but synergizes with CD3 stimulation to fully activate p38 MAPK
in preactivated proliferating T cells (Salmon et al., 1997). However, it has also been
reported that p38a can be activated by CD28 stimulation alone in purified human CD4+
peripheral blood T cells (Schafer et al., 1999).
T cell proliferation and cytokine production usually require stimulation via both the
TCR/CD3 complex and the CD28 costimulatory receptor. It has been shown that p38
MAPK activation mediates both TCR- and CD28-induced signalling in primary mouse
T cells. Ligation of TCR or CD28 results in only modest p38 MAPK activation, whereas
TCR and CD28 synergize upon coligation to elicit enhanced p38 MAPK activation.
PMA/Ca2+ ionophore costimulation, which mimics TCR/CD28-mediated signalling,
fully activates p38 MAPK in primary mouse T cells, but not JNK (Zhang et al., 1999).
Cross-linking CD40 rapidly stimulated the p38 MAPK-MK2 pathway in both human
tonsillar B cells and multiple B cell lines. SB203580 treatment completely prevented
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MK2 activation and strongly perturbed CD40-induced tonsillar B cell proliferation.
SB203580 also selectively reduced CD40-induced CD54/ICAM-1 expression, whereas
CD40-dependent expression of CD40 and CD95/Fas and four CD40-responsive genes
cIAP2, TRAF1, TRAF4/CART and DR3 were unaffected (Craxton et al., 1998).
However, CD40-mediated NF-kB binding was not affected by SB203580, suggesting
that NF-kB may not be a direct target for the CD40-induced p38 MAPK pathway. This
showed that the p38 MAPK pathway is required, at least in part for CD40-induced NF-
kB activation and that the induction of CD40-responsive genes occurs via both p38
MAPK-dependent and -independent pathways (Craxton et al., 1998).
3.1.5 Autophosphorylation and Autoactivation of p38a
Very recently, a new activation mechanism for p38a has been reported. It has been
found that interaction of p38a with TAB1 [transforming growth factorb-activated
protein kinase 1 (TAK1)-binding protein 1] leads to autophosphorylation and activation
of p38a (Ge et al., 2002). Further experiments demonstrated that p38a kinase activity is
not required for TAB1 binding and the effects of TAB1 on p38a are independent of its
effects on TAK1. This indicated that TAB1-mediated p38a phosphorylation is most
likely an intramolecular reaction.
It was shown that TAB1-induced p38 phosphorylation was sensitive to SB203580 in
vitro and in vivo. Therefore, it was also examined whether TAB1-dependent
p38a phosphorylation induced by extracellular stimuli was sensitive to SB203580.
SB203580 inhibited p38a phosphorylation induced by both TNF or peroxynitrite in
HEK 293 cells.
The effect of SB203580 on anisomycin-induced p38a phosphorylation was less
pronounced, and SB23580 had almost no effect on hyperosmolarity (sorbitol)-induced
phosphorylation of p38a. In RPMI 8226 cells (a human B cell line), SB203580
treatment inhibited CpG- and LPS-induced phosphorylation of p38a, but had no effect
on phosphorylation induced by bacterial lipoprotein via various toll-like receptors (Ge et
al., 2002). This indicated that SB203580 functioned differently in the cells treated with
different stimuli. It does not really function differentially – it always inhibits p38, so it
does not inhibit activation by MKK3/6 but autoactivation of p38. Thus, the differential
sensitivity to SB203580 is most likely a reflection of differing p38a activation
mechanisms.
This finding provides an example of signal transduction that is controlled not only by
enzymes, but also by nonenzymatic adapters, scaffolds and other "inert" proteins. The
autoactivation of p38 MAP kinases facilitated by interaction with regulatory molecule(s)
could be an important alternative activation pathway operating in parallel with kinase
cascades in regulating intracellular signalling (Ge et al., 2002).
3.2   The p38 Inhibitors
A series of pyridinyl imidazoles, which were originally identified by their ability to
suppress inflammatory cytokine synthesis, can specifically inhibit p38 by binding to the
ATP pocket (Lee et al., 1994; Young et al., 1997). All imidazole based p38 inhibitors
contain the elements of a 4-aryl-5-(pyridin-4-yl) imidazole (Gallagher et al., 1997) and
among them SB203580 has been widely used to elucidate the roles of p38 in the
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research. The effect of representative inhibitors on p38 activity is summarised in Table
1-4 (Lee et al., 1999).
The crystal structure and p38-mutant analysis demonstrate that beside the ATP-binding
motif, the Thr106 residue is a major determinant for p38a/b inhibitor specificity. The
His107, Leu108 and Met109 residues increase the binding affinity of imidazole based
inhibitors (Gum et al., 1998; Lisnock et al., 1998; Tong et al., 1997). The substitution of
the Thr106 residue of p38a by a Met residue abolishes the binding of the inhibitor and
leads to SB-insensitive kinase, whereas the substitution of of JNK Met106 residue by a
Thr residue confers it a SB-sensitivity (Gum et al., 1998; Eyers et al., 1999).
Table1-4: The p38 activity of representative inhibitors
____________________________________________________________________
Compound p38 (IC50, nM)
   ____________________________________________________________________
SKF86002 1500
SB203580     48
L-167307        5,0
Compound 1     83
SB220025     19
SB210313 1300
SB216385   480
RWJ68354        9,0
____________________________________________________________________
Binding of SB203580 to p38 blocks the activity of p38 but not its activation by MKK
but by TAB1 (Ge et al., 2002).  After anisomycin, sorbitol and sodium arsenite
stimulation of Jurkat T, 3T3 or Hela cells, p38a is phosphorylated and activated.
SB203580 also fails to block activation of p38 in arsenite activated 293 T cells, while it
blocks the export of nuclear p38 to the cytoplasm (Ben-Levy et al., 1998). Nevertheless
a decrease of p38a phosphorylation on its Tyr residue in the presence of 20 mM
SB203580 after 45 min UV irradiation, anisomycin and sodium arsenite treatment has
been observed ( Lim et al., 1998).
At the concentration where p38a is inhibited, neither JNK nor ERK are blocked by
SB203580 (Cuenda et al., 1995; Lim et al., 1998). A high level of selectivity for
inhibition of p38 versus some protein kinases has been reported and is shown in table
1-5. The selectivity ratios based on IC50 often exceed 1000. SB203580 is equipotent
against p38a and p38b. Other closely related MAPKs, such as p38g, p38d, JNK1 and
ERK2 weakly inhibited if at all. The most potent inhibition reported for non-p38
MAPKs by SB203580 are c-Raf (IC50=360) and JNK2b1(IC50=280).
3.3 p38 MAPKs Upstream Activators: MKKs
Like other MAPKs, p38 MAPKs are activated when the Thr-Gly-Tyr motif which
located between subdomains VII and VIII of the kinases are phosphorylated by dual
kinases, the MAP kinase kinase (MKKs). Among the upstream kinases, MKK3 and
MKK6 activate one or more of p38 isoforms. MKK3 has been shown to selectively
activate p38a and p38g (Enslen et al., 1998), while MKK6, which is 80% homologous
to MKK3, activates all four isoforms (Goedert et al., 1997; Cuenda et al., 1997).
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It is also reported that MKK4 activates both p38a and p38d (Jiang et al., 1997) and
MKK7 can activate p38d (Hu et al., 1999). But it seems that MKK3 and MKK6 are
likely to have important roles for the activation of p38 MAPKs under physiological
conditions.
The substrate selectivity of MKKs may be a reason why each MKK has a distinct
function.
The recombinant adenoviruses expressing activated MKK6bE are much more efficient
than MKK3bE in inducing apoptosis of Jurkat T cell (Huang et al., 1997), while when
expressed in cardiac myocytes, MKK3bE  has more apoptotic effect (Wang et al, 1998).
Table 1-5: The sensitivity profile among protein kinases to SB203580
____________________________________________________________________
Kinase Equivalent SB203580 Reference
Residue (IC50, nM)
____________________________________________________________________
p38a T 48 Young et al., 1997
p38b T 50 Kumar et al., 1997
p38g M    >10 000 Kumar et al., 1997
p38d M    >10 000 Kumar et al., 1997
JNK1 M       ~5000 de Laszlo et al., 1998
JNK2b1 M           280 de Laszlo et al., 1998
JNK2a2 M         1900 de Laszlo et al., 1998
ERK2 Q  >100 000 Cuenda et al., 1995
PKB S/T           500 Lali et al., 2000
MEK1 M      61 000 Cuenda et al., 1995
Cdc2 F    >50 000 Cuenda et al., 1995
TGFbI S      20 000 Eyers et al., 1998
TGFbII T      40 000 Eyers et al., 1998
c-Raf T           360 de Laszlo et al., 1998
MK2 M    >10 000 Cuenda et al., 1995
LCK T      20 000 Eyers et al., 1998
         _____________________________________________________________________
The selection of the appropriate MKKs varies with both the stimulus and the cell type.
Normally the MKKs are activated in response to the cellular stresses and cytokines, but
with some differences: MKK3 and MKK4 are preferentially activated by osmotic shock
and anisomycin; while MKK6 is normally responsive to UV irradiation, osmotic shock,
anisomycin and IL-1b (Meier et al., 1996). In rat PC12 and 293 cells, MKK3 and
MKK6 phosphorylate p38a to the same extend whereas in KB cells, THP1 monocytes
and rabbit skeletal muscle, MKK6 represents 95% of the p38a activator activity
(Cuenda et al., 1996; Meier et al., 1996)
The names used for MKKs in different experimental systems are summarized in table
1-6.
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MKK4 SAPKK1, SKK1, SEK1, JNKK
MKK5 MEK5
MKK6 SAPKK3, SKK3, MEK6
MKK7 SKK4
3.4 Further Upstream Activators
At least six further upstream activators capable of activating the MKK-p38 MAPK
pathway in vitro or in co-transfection experiments have been identified, namely MAP
kinase kinase kinases (MKKKs).
These include: (summarized in table 1-7)
MUK MAPK kinase upstream kinase
MLK2/3 mixed lineage kinase2/3
MTK1 MAP three kinase 1
TAK1 TGFb-activated protein kinase-1
ASK1 apoptosis signal regulating kinase 1
Normally, overexpression of these MKKKs leads to activation of both p38 and JNK
pathways, that maybe the reason why p38 and JNK are often conactivated. There are
different names of MKKKs in different experimental systems, they are summarized in
the table 1-8.
The MKKKs are further diversified. For example, MTK1 is a major mediator of
environmental stresses that activate the p38 MAPK pathway (osmotic shock, UV and
anisomycin), but not cytokines (TNF) (Takekawa et al., 1997). Overexpression of ASK1
induced apoptotic cell death. ASK1 may be a key element in the mechanism of stress-
and cytokine-induced apoptosis (Ichijo et al., 1997 ).
It has been reported that both small and large GTP-binding proteins are involved in the
p38 signal cascade. Rac and Cdc42 are members of the Rho family of small GTP-
binding proteins, they were identified as potential regulators of the p38 pathway (Zhang
et al., 1995 ; Bagrodia et al., 1995). p21-activated kinases (Paks) are serine/threoinie
protein kinases, the human homologues of Ste20. Pak can be activated by binding to its
upstream regulators, Rac and Cdc42 (Bagrodia et al., 1995). Pak1 stimulates p38
activity. A dominant negative Pak1 suppresses both IL-1- and Rac/Cdc42-induced p38
activity (Zhang et al., 1995). MLK3 contains a Rac and Cdc42 binding motif, so Rac
and Cdc42 may directly activate MLK3 (Tibbles et al., 1996).
Both fMet-Leu-Phe (FMLP) and platelet-activating factor (PAF) bind to the neutrophil
cell surface via members of the seven trans-membrane spanning G-protein linked
receptor family. Interaction between these chemokines and the G-protein-coupled
receptors can lead to p38 pathway activation (Nick et al., 1997). FMLP strongly
activates both p38 MAPK and ERK, while PAF preferentially activates p38 MAPK. The
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activation of p38 MAPK by FMLP and PAF appears to occur through the activation of
MKK3 (Nick et al., 1997).
Table 1-7: MKKKs of p38 pathway
_____________________________________________________________________
MKKKsActivated Cell Type Reference
MKKs
_____________________________________________________________________
MLK2 MKK3/6 KB cells, COS-1 Cuenda and Dorow, 1998
MTK1                MKK3/6/4 COS-7, Hela Takekawa et al., 1997
DLK COS-1 Hirai et al., 1997
NIH3T3 cells Fan et al., 1996
MLK-3              MKK6 Tibbles et al., 1996
ASK1                MKK4/3/6 Ichijo et al., 1997
TAK1                MKK3/6 COS7 Moriguchi et al., 1996
MKK6 Mv1Lu, C2C12 Hanafusa et al., 1999
_____________________________________________________________________










3.5 p38 MAP Kinases Inactivation
The magnitude and duration of activation of the MAPKs are properly regulated and
have a great effect on determination of the fates and responses of cells. MAPKs are
regulated by dual phosphorylation and dephosphorylation within the motifs TXY,
respectively, by several upstream dual specificity kinases (MKKs) and several types of
protein phosphatases.
MAP kinase inactivation is mediated by dephosphorylation via specific MAP kinase
phosphatases (MKPs). There is an emerging family of dual specificity phosphatases
acting on the MAPK superfamily. Eleven members of this group of dual specificity
phosphatases have been reported, which are summarized in table 1-9.
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The MKPs share sequence homology, but each has distinct properties concerning
substrate specificity, tissue distribution, subcellular localization, and inducibility by
extracellular stimuli. MKP-1, MKP-2, PAC1 and hVH3 localize in the nucleus, whereas
MKP-3, MKP-4, and MKP-X localize in the cytoplasm; MKP-5 is distributed both in
the cytoplasm and the nucleus (Table 1-9).
Among these MKPs, MKP1 inactivates several MAPKs, such as ERK, JNK and p38
(Sun et al., 1993). M3/6 is the first phosphatase of this family to display highly specific
inactivation of JNK/SAPK and p38 MAP kinases. In contrast to M3/6, the dual
specificity phosphatase MKP-3 is selective for inactivation of ERK family MAP kinases
Table 1-9: Members of MKPs
_______________________________________________________________________________
MKP Other Names Localization Reference
_______________________________________________________________________________
MKP-1 3CH134/CL100 nucleus Keyse and Emslie,1992
MKP-2 hVH2, TYP-1 nucleus Guan and Butch, 1995
Misra-Press et al., 1995
MKP-3 Pyst1, rVH6 cytoplasm Muda et al., 1996
Groom et al., 1996
MKP-4 Pyst3 cytoplasm Muda et al., 1997
MKP-5 cytoplasm & nucleus Tanoue et al., 1999
MKP-6 Marti et al., 2001
MKP-7 cytoplasm Tanoue et al., 2001b
MKP-7 cytoplasm & nucleus Masuda et al., 2001
MKP-X Pyst2 cytoplasm Muda et al., 1996
Groom et al., 1996
M3/6  hVH5 Muda et al., 1996b
Theodosiou et al., 1996
VHR Ishibashi et al,. 1992
PAC1 nucleus Rohan et al., 1993
hVH3 B23 nucleus Kwak et al., 1995
Ishibashi et al., 1994
        ____________________________________________________________________ ____________
(Muda et al, 1996b). Another dual specificity phosphatase, MKP 5, was reported to
inactivate p38 and JNK (Tanoue et al., 1999). Recently, some new MKPs were reported
to be found, MKP-6 (Marti et al., 2001) and two MKP-7 (Masuda et al., 2001; Tanoue et
al., 2001b), they all inactivates MAP kinases. In COS-7 cells, expression of MKP-7
(Masuda-MKP-7) suppressed the activation mainly on JNK, p38 and ERK were also
inactivated by MKP-7 (Masuda-MKP-7) (Masuda et al., 2001). Whereas Tanoue et al
reported that their MKP-7 (Tanoue-MKP-7) is most similar to hVH5 in the primary
sequence and predominantly localized in the cytoplasm when expressed in cultured
cells. MKP-7 (Tanoue-MKP-7) possesses a NES sequence in the C-terminal stretch
region, which regulates the subcellular localization of the molecule. MKP-7 (Tanoue-
MKP-7) binds to and inactivates p38 MAPK and JNK, but not ERK.
Tanoue et al also proposed a tentative classification of MKPs according to the primary
sequence of their MAPK-docking sites (Fig. 1-1) and they also found that MKPs have
the substrate specificity toward the isoforms of the p38 MAPKs. CL100/MKP-1, MKP-
5 and MKP-7 (Tanoue-MKP-7) selectively bind to and inactivate p38a and b, but not d
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or g. Then, inactivation of p38 g and d in cells might be achieved by other phosphatases,
such as serine/threonine protein phosphatases type 2C (PP2C) or protein tyrosine
phosphatases (PTPs) (Tanoue et al, 2001b).
Fig. 1-1: The tentative classification of MKPs (Tanoue et al, 2001b): A, a proposed
classification of MKPs according to the primary sequence of their MAPK-docking sites.
The underlined amino acids are the positively charged amino acids which are supposed
to be important for the docking interaction. The consensus sequence of each group is:
XXRRRA(K/R) for the group containing CL100/MKP-1; XXXRRY(R/K)(Q)R/K(G)
for the group containing MKP-3; X(K/R)RRLQQYK for the group containing MKP-7
(X is a hydrophobic residue, and Y is any residue except for K or R). B, MKPs show the
substrate specificity toward the isoforms of the p38 MAPK family.
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MKPs are potential negative regulators of MAPK cascades and as such are assumed to
be involved in carcinogenesis by regulating cell proliferation and apoptosis. As a result,
all human MKP genes have been mapped. Among them, MKP-2 and MKP-3 are
mapped to a gene locus encoding tumor suppressors for prostate and pancreatic cancer,
(Furukawa et al., 1998; Smith et al., 1997). MKP-X and MKP-5 are mapped to 3p21
(Smith et al., 1997) and to 1q41 (Masuda et al., 2000), respectively, where frequent
deletions are reported in a number of different tumors. Masuda-MKP-7 is mapped to
human chromosome 12p12 (Masuda et al., 2001) while Tanoue-MKP-7 gene is
mapped to human chromosome 12 between the BAC clones, RPCI11-180M15
(accession number AC008115) and RP11-161A14 (accession number AC022276)
(Tanoue et al., 2001b). Leptomycin B (LMB) is a specific inhibitor of nuclear export.
MKP-7 is the first identified leptomycin B-sensitive shuttle MKP. Interestingly MKP-7
(Masuda-MKP-7) contains predicted functional motifs such as a NES and nuclear
localization signals (NLSs), suggesting that it functions as a shuttle protein and a MAPK
phosphatase (Masuda et al., 2001).
In addition to MKPs, protein tyrosine phosphatase (PTPase) and a serine/threonine
protein phosphatase type 2C (PP2C) inactivated HOG1 pathway in yeast (Posas et al.,
1996; Wurgler-Murphy et al., 1997). It is also reported that a human protein
phosphatase, PP2Ca, negatively regulates the human stress-responsive p38 and JNK
pathway. In vivo and in vitro studies indicate that PP2Ca dephosphorylates both MKK6,
MKK4 and a p38 (Takekawa et al., 1998)
4.  p38 MAPKs Targets: Downstream substrates of p38 MAP kinases
The main downstream substrates of p38 MAPKs are some protein kinases and
transcription factors.
4.1  Protein Kinases
(1)   MK2 and MK3/3pk
MK2 and MK3 have been identified as physiological substrates for p38 MAPK.
p38a activated MK2 and this activation was inhibited by SB203580 in vivo ((Rouse et
al., 1994). MK3 shares about 70% amino acid identity to MK2. MK3 was
phosphorylated by both p38a and p38b. The activation was also blocked by SB203580
in Hela cells (McLaughlin et al., 1996). MK2 or MK3 is activated rather poorly by p38 g
and p38d (Cuenda et al., 1997; Kumar et al., 1997).
The two isoforms of MK2 (63 kDa and 50 kDa) were described as ERK substrates first
(Stokoe et al., 1992). Later, it was found that these two isoforms were coming from
differential splicing of a 3.3 kb mRNA transcript (Stokoe et al., 1993). Mouse MK2 is
activated by phosphorylation on Thr205 and Thr317 (Engel et al., 1995).
MK2 has a broad substrate specificity, phosphorylating proteins and peptides at serine
residues that lie in Xaa-Xaa-Hyd-Xaa-Arg-Xaa-Xaa-Ser-Xaa-Xaa motif, where Hyd is a
bulky hydrophobic residue (Phe > Leu > Val >> Ala) (Stokoe et al., 1993).
It has been found that under heat-shock conditions in mouse Ehrlich ascites tumor
(EAT) cells and after treatment of human MO7 cells with tumor TNF-a, MK2 is
activated. Further experiments showed that MK2 is responsible for phosphorylation of
sHsps (Hsp25/27) both in vitro and in vivo (Engel et al., 1995b).
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It has been reported that the activated MK2 and MK3 phosphorylate various relevant
substrates, which including Hsp25/27; Lymphocyte-specific protein 1 (LSP1); CREB;
ATF1; serum response factor (SRF); tyrosine hydroxylase; 5-lipoxygenase (5-LO); a
basic helix-loop-helix (bHLH) transcription factor E47; and an ETS transcription factor
ER81. These substrates are summarized in table 1-10.
The bHLH transcription factors E12 and E47 are encoded by the E2A gene and are
generated by differential splicing of E12- and E47-specific bHLH-encoding exons. It is
reported that MK3 and MK2 interact with E47 in vivo and are able to phosphorylate E47
in vitro, indicated that these kinases are regulators of E47 activity (Neufeld et al., 2000).
The E47 amino acid sequence shows four potential minimal consensus motifs for
phosphorylation by MKs, three in the extreme N terminus and one at Ser-529 (Sloan et
al., 1996)
5-lipoxygenase (5-LO) catalyzes important steps in the synthesis of a group of
inflammatory mediators, leukotrienes. It has been reported that 5-LO is a downstream
target of MK2 and MK3 (Werz et al., 2000).
Table 1-10: Some substrates of MK2/3 and their phosphorylation residues
_________________________________________________________________________
Substrate of MK2/3 phosphorylation residues Reference
_________________________________________________________________________
Hsp25 (murine) Ser15, Ser86 Stokoe et al., 1992
Hsp27 (human) Ser15, Ser78 and Ser82 Stokoe et al., 1992
LSP1 Ser204, Ser252 Huang et al., 1997
CREB Ser133 Tan et al., 1996
ATF1 Ser63 Tan et al., 1996 
Sun et al., 1996
SRF Ser103 Heidenreich et al., 1999
tyrosine hydroxylase Ser19 Thomas et al., 1997
5-LO Werz et al., 2000
E47 more Neufeld et al., 2000
(such as 3  in the extreme Sloan et a.l, 1996
N terminus and one at Ser529)
ER81 Ser191, Ser216 Janknecht, 2001
_________________________________________________________________________
ER81 is a ETS transcription factor and is identified as a novel target of MK2. By
phosphorylating ER81 on Ser191 and Ser216, MK2 can inhibit ER81 transcriptional
activity in a cell type-specific fashion (Janknecht, 2001). However, MK2 can also
interfere with ER81-mediated transcription independently of serine 191 and serine 216
phosphorylation. (Janknecht, 2001).
MK2 ko mice were generated and embryonic fibroblast (MEF) cell line was established
from the MK2 ko mice in our group (Kotlyarov et al., 1999). The MK2 ko mice show
increased stress resistance and survive for LPS-induced endotoxic shock. This is due to
a reduction of approximately 90% in the production of TNF-a and not to a change in
signalling from the TNF receptor. It was also demonstrated that MK2 regulates
biosynthesis of TNF-a at a post-transcriptional level (Kotlyarov et al., 1999). Using
MK2 -/- MEF, it was found that MK2 was not involved in the phosphorylation of CREB
and ATF1 (Rolli et al., 1999).
(2)   MK5/PRAK
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MK5 or PRAK (p38-regulated/activated kinase) was identified as serine/threonine
kinase phosphorylated by p38 independently by two groups in mouse and human
leading to the two different names (Ni et al., 1998; New et al., 1998). Meanwhile, it is
highly probable that PRAK is the human homologues of murine MK5. MK5 and PRAK
are compared in table 1-11.
PRAK, like MK2, phosphorylates Hsp27 at the functionally relevant sites (New et al.,
1998). And it was suggested that p38a and p38b are in vivo regulators of PRAK (New
et al., 1998). Although MK5/PRAK was found three years ago, we still know very less
about this kinase.





amino acid 473 471
molecular mass 54 kDa 54 kDa
tissue distribution heart, brain, lung, liver, heart, brain, lung, liver,
skeletal muscle, kidney, skeletal muscle, kidney
testis placenta, pancreas
cell line distribution 293, A549, Hela, Jurkat, HepG2







be phosphorylated by ERK and p38 p38a and p38b
activated by ERK and p38(in vitro) MKK6(E), p38a and p38b
relevant site Thr182 Thr182
LXTP motif LMTP LMTP
phosphorylates Hsp27/25 (in vitro and in vivo)




Reference Ni et al., 1998 New et al., 1998
_____________________________________________________________________________
(3) MAPK interaction protein kinase 1 (MNK1)
MNK1 and MNK2 are structurally similar to MK2 and MK3. MNK1 binds tightly to
ERK1 and p38, whereas MNK2 only binds to ERK1/2 (Waskiewicz et al., 1997). Both
ERK and p38 phosphorylate and activate MNK1 in response to peptide growth factors,
phorbol esters and environmental stresses. The activation by these stimuli is
differentially inhibited by PD98059 and SB202190 (Fukunaga and Hunter, 1997). It has
been found that activated MNK1 phophorylates eIF-4E at the physiologicall relevant
site Ser209 both in vitro (Waskiewicz et al., 1997; Wang et al, 1998b) and in vivo
(Knauf et al., 2001). The phosphorylation of eIF4E via MNK1 is mediated via the
activation of either the ERK or p38 pathway and the kinase activity of MNKs,
eventually through phosphorylation of eIF4E, may serve to limit cap-dependent
translation under physiological conditions (Knauf et al., 2001).
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(4) MSK1
MSK1 is a protein serine/threonine kinase that contains two protein kinase domains in a
single polypeptide. Like MNK1, MSK1 is activated both in vitro and in vivo by either
ERKs or p38, it is activated by both stress and mitogen (Deak et al., 1998; New et al.,
1999). In HeLa, PC12 and SK-N-MC cells, PD 98059 and SB 203580 are both required
to suppress the activation of MSK1 by TNF, NGF and FGF. MSK1 is localized in the
nucleus of unstimulated or stimulated cells, and phosphorylates CREB at Ser133 with a
Km value far lower than PKA, MK1 and MK2. This suggests that MSK1 may mediate
the growth-factor and stress-induced activation of CREB (Deak et al., 1998).
MSK1 also can phosphorylate histone 2B, histone 1, histone H3 and HMG-14 in vitro
(New et al., 1999; Thomson et al., 1999). The phosphorylation of histone H3 on serine
10 and HMG-14 on serine 6 would induce the immediate-early (IE) gene expression in
response to a wide variety of stimuli. This induction can be blocked by the protein
kinase inhibitor HB89, PD098059 or SB203580. MSK1 may mediate the nucleosomal
response through ERK and p38 pathway, but not JNK (Thomson et al., 1999).
MSK1, MSK2 and double knockouts (both MSK1 and MSK2) mice were produced
recently. Experiments using MEFs derived from these ko mice showed that MSK1 and
MSK2 are required for the stress-induced phosphorylation of CREB and ATF1. The
knockout of both MSK1 and MSK2 resulted in a 50% reduction in c-fos and junB gene
transcription in response to anisomycin or UV radiation but only a small reduction in
response to TPA or EGF in fibroblasts. The transcription of egr1 in response to both
mitogenic and stress stimuli, as well as stress-induced apoptosis, was unaffected in the
MSK1/MSK2 double knockout (Wiggin et al., 2002).
4.2 Transcription Factors
Several transcription factors can be phosphorlyated and activated by p38 pathway. And
many of the transcriptional events stimulated by p38 MAPK may also be mediated by
the activation of the protein kinases which are p38 downstream direct targets, such as
MK2, MNK1 and MSK1.
(1)   ATF2
ATF2 is a member of the ATF/CREM family. All members of this family contain a
DNA binding domain consisting of a cluster of basic amino acids and a leucine zipper
region, the so called b-ZIP (Busch and Sassone-Corsi, 1990). They form homodimers or
heterodimers through their leucine zipper regions and bind to CRE. p38b has been
proposed to phosphorlyate ATF2 with higher efficiency than p38a (Jiang et al., 1997;
Stein et al., 1997), while others have shown that all four isoforms phosphorlyate ATF2,
as well as Elk1 and SAP1, with equal efficiency (Cuenda et al., 1997; Goedert et al.,
1997;  Kumar et al., 1997). p38 MAPKs and JNK phosphorylated ATF2 at Ser90, as
well as at Thr69 and Thr71 (Cuenda et al., 1997). It has been shown that p38 activated
ATF2 was involved in the TNFR1-induced gene expression of TNF-a (Brinkman et al.,
1999) and might play an important role in the TGF-b signalling via TAK1 and p38
pathway (Sano et al., 1999).
Using GST-ATF2-(1-115), the kinetic mechanism for the dual phosphorylation has been
studied. It has been found that the dual phosphorylation of the two residues within GST-
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ATF2-(1-115), Thr-69 and Thr-71, occurs by a two-step mechanism where p38
dissociates from the protein after each phosphorylation event. The kinetics of this
process is predicted to have important implications for the activation of ATF2 by p38
in vivo and highlights the potential that two-step distributive mechanisms have for
controlling the amplitude sensitivity of signal transduction pathways (Waas et al., 2001).
(2)   myocyte enhancer factor 2C and 2A (MEF 2C and 2A)
The MEF2 family is composed of four members: MEF2A, MEF2B, MEF2C, and
MEF2D. Members of the MEF2 family of transcription factors bind as homo- and
heterodimers to the MEF2 site found in the promoter regions of numerous muscle-
specific, growth- or stress-induced genes (Han et al., 1997b). MEF2A and MEF2C
exhibit about 56% identity sequence conservation throughout their lengths (Yang et al.,
1999). MEF2A and MEF2C have been shown to be phosphorlyated and activated by
p38 MAPKs (Han et al., 1997b; Zhao et al., 1999). Transcriptional activation in vivo of
MEF2A and MEF2C by p38a and p38b requires a kinase docking domain, D-domain
(Yang et al., 1999). The Thr312 and Thr319 residues of MEF2A and the Ser287, Thr293
and Thr300 residues of MEF2C are necessary for the activation of p38 MAPKs (Han et
al., 1997b; Zhao et al., 1999). With MEF2C, selective phosphorlylation of residue
Thr293 is a tissue-specific activating signal in differentiating myocytes (Wu et al.,
2000). Among the four p38 isoforms, p38a is the most potent kinase for MEF2A (Zhao
et al., 1999).
In monocytic cells, LPS increases the transactivation activity of MEF2C through p38-
catalysed phosphorylation. Activation of MEF2C results in increased c-jun gene
transcription. This suggested that p38 may influence host defence and inflammation by
regulating c-Jun production (Han et al., 1997b). It has been shown that the p38 MAPK
pathway promotes skeletal muscle differentiation at least in part via activation of
MEF2C (Zetser et al., 1999; Wu et al., 2000).
(3)   ternary complex factor (TCF) Proteins: Elk1 and SAP1
TCFs are a subgroup of Ets-domain transcription factor family. Elk1 and SRF accessory
protein 1 (SAP1) are members of the TCF family.
Elk1 binds to Ets sites in the pip92 (IE gene) promoter (Latinkic and Lau, 1994). It has
been shown that Elk1 was involved in the pip92 expression during anisomycin-induced
cell death in fibroblast NIH3T3 cells (Chung et al., 2000). JNK, p38 MAPK and ERK
all can phosphorylate Elk1 (Janknecht and Hunter, 1997; Whitmarsh et al., 1997), and
high levels of JNK and p38 activities have been correlated with the induction of
apoptosis in many instances (Xia et al., 1995; Chen et al., 1996; Chung et al., 2000).
It has been reported that Elk-1 is barely activated by p38, most likely because the critical
residues Ser383 and Ser389 are poorly phosphorylated by p38 MAP kinase. In contrast,
SAP1 is efficiently phosphorylated by p38 MAP kinase on residues Ser381 and Ser387
(Janknecht and Hunter, 1997). SAP1 contains two domains which specify substrate
phosphorylation. The D-domain serves to promote selective targeting of ERK2, p38a,
and p38b; whereas the second domain, FXF motif promotes targeting by ERK2 and, to a
lesser extent, p38a, but not p38b. The FXF motif is conserved between SAP1 and Elk1
(Galanis et al., 2001).
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SAP1 could be an important target for mitogens, stress and apoptotic signals to elicit a
nuclear response (Janknecht and Hunter, 1997).
(4)   C/EBP(CCAAT/enhancer-binding protein) Family: CHOP (cAMP response
element-binding protein-homologous protein/growth arrest DNA damage 153
(CHOP/GADD153)) and C/EBPb
Some of C/EBP family of transcription factors have been reported to be controlled by
p38 MAPK. CHOP is a member of the C/EBP family of transcription factors and
accumulates under conditions of stress and mediates effects of cellular stress on growth
and differentiation (Wang and Ron, 1996). In response to stress, CHOP undergoes
phosphorylation in vivo on two adjacent serine residues 78 and 81, which is blocked by
SB203580. Phosphorylation of CHOP positively correlates with its transcription
activity. CHOP thus serves as a link between p38 and cellular growth and differentiation
(Wang and Ron, 1996).
Another member of C/EBP family, C/EBPb, is a substrate of p38. In 3T3-L1 fibroblasts,
inactivation of p38 during only the initial stages of differentiation can prevent
conversion of the fibroblasts to adipocytes (Engelman et al., 1998).
4.3 Others
(1)   cytosolic phospholipase A2 (cPLA2)
cPLA2 is responsible for thrombin-stimulated mobilization of arachidonic acid for the
synthesis of thromboxane A2 in human platelets. It has been shown that cPLA2 is
phosphorylated and activated p38a, so cPLA2 is thought to be a physiological target of
p38a (Kramer et al., 1996). Ser505 and Ser727 of cPLA2 could be phosphorylated
during its activation. Interestingly, it has been found that Ser505 is phosphorylated by
p38 protein kinase, mainly by p38a; whereas Ser727 is phosphorlyated not by p38, but
by a p38 direct downstream target protein kinase, such as MNK1 or a closely related
protein kinase (Hefner et al., 2000).
(2)   Stathmin/Op18
Stathmin, a cytoplasmic protein that is linked to regulation of microtubule dynamics
and is a substrate of several intracellular signalling kinases, was also identified to be a
substrate of p38d in a solution kinase assay. Osmotic stress activates p38d has been
shown to phosphorylate stathmin on Ser25 and Ser38 both in vitro and in cells
(Parker et al., 1998). It has been reported that TNF-induced microtubule stabilization is
mediated by hyperphosphorylation of oncoprotein 18 (Op18, stathmin) and that this
promotes cell death in the mouse fibrosarcoma cell line L929 (Vancompernolle et al.,
2000).
5.   Subcellular Localization of p38 MAPKs and Their Downstream Targets
Subcellular localization of p38 MAPK and their downstream targets or the nuclear-
cytoplasmic transport of p38 MAPKs may show their different physiological functions
in certain conditions. In different cells and in different experimental systems, the
subcellular localization may also be different.
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Immunofluorescence microscopy demonstrated that over-expressed p38 MAP kinase is
present in both the nucleus and cytoplasm. Activation of the signalling cascade by UV
irradiation does not cause marked redistribution of p38 MAP kinase from the cytoplasm
to the nucleus in COS cells (Raingeaud et al., 1995). In transfected cells, GFP-MK2 is
located predominantly in the nucleus. Upon stress, it rapidly translocates to the
cytoplasm and the translocation is blocked by SB203580 and leptomycin B (Engel K et
al, 1998). Following phosphorylation of MK2, nuclear p38 is exported to the cytoplasm
in a complex with MK2. The cytoplasm translocation of MK2 requires phosphorylation
by p38 without a requirement for MK2 activity (Ben-Levy et al., 1998). MK2 serves
both as an effector of p38 by phosphorylating substrates and as a determinant of cellular
localization of p38. Nuclear export of p38 and MK2 may permit them to phosphorylate
cytoplasmic substrates, such as eukaryotic initiation factor (eIE)-4E and PHAS-1.
Both endogenous and GFP-MK5 are in nuclear in resting cells. Like MK2, MK5 also
has a functional NLS and a NES. Treatment of cells with arsenite results in nuclear
export of MK5. Time studies showed that this transport was much slower then MK2.
Sorbitol induced nuclear export of MK2, but not of MK5. Arsenite-induced export of
MK5 is inhibited by leptomycin B (Prof. Ugo Moens and Dr. Ole Morten Seternes’
observation, unpublished). Transfection of GFP-MK5 or co-transfection of GFP-MK5
and p38 in Hela cells, after stimulation of arsenite, we checked the export of MK5 and
got the comparable results.
6.   p38 Pathway Functions
6.1 Cytokines: Production and Gene Expression
(1)   IL-1b and TNF-a 
Synthetic MALP-2 can activate p38 and the activation of p38 induces mRNA synthesis
and protein secretion of IL-1b and TNF-a in human monocytes/macrophages and the
murine macrophage cell line RAW 264.7 (Garcia et al., 1998). Experiment with MK2
ko mice showed that p38 through the activation of MK2, controls IFN-g and TNF-a
expression in spleen cells at a post-transcriptional level (Kotlyarov et al., 1999). It has
also been reported that inhibition of p38 MAPK pathway by SB203580 reduces LPS-
induced TNF-a production not only by affecting the translation level, but also by
destabilizing TNF-a mRNA. SB203580 could reduce more than 50% of TNF-a mRNA
expression in differentiated THP-1 cells and almost 80% in human blood monocytes
(Rutault et al., 2001).
(2)   IL-4
Using purified human CD4+ peripheral blood T cells, it has been shown that CD28
stimulation alone activates p38a. SB 203580 blocked CD28-induced cell proliferation
as well as CD3/CD28-induced IL-4 production, largely at the mRNA level (Schafer et
al., 1999).
(3)   IL-5
IL-5 synthesis is dependent on p38 MAPK activity and SB203580 inhibited IL-5
synthesis, suppressed IL-5 mRNA expression in human Th cells (Mori et al., 1999).
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(4)   IL-6
IL-1b is a potent activator of IL-6 synthesis in human fibroblast-like synoviocytes
(FLSs) (Guerne et al., 1989). In response to IL-1b stimulation in human FLSs, p38 was
activated and was found to be involved in IL-6 synthesis at the transcription level by
stabilizing IL-6 mRNA, without affecting the rate of IL-6 gene transcription (Miyazawa
et al., 1998). Using of SK&F86002, an cytokine-suppressant anti-inflammatory drug
(CSAID), p38 was found also being involved in TNF-a -induced IL-6 production in
human osteoblastic cells (SaOS2) (Blanque et al., 1997). In MK2 ko mice, IL-6 mRNA
level is greatly reduced compared to the wild type (Kotlyarov et al., 1999).
(5)   IL-8
Mycoplasma fermentans lipid-associated membrane proteins (LAMPf) induce the
production of high levels of IL-8 by THP-1 and PMN cells at the same extent as LPS,
and both ERK1/2 and p38 cascades play a key role in the production of IL-8 (Marie et
al., 1999). It is also reported that MKK6 pathway contributes to induction of IL-8
synthesis by stabilizing its mRNA (Holtmann et al., 1999).
(6)   IL-12
MKK3 ko macrophages have a deficit in LPS-induced p38 MAPK activation, in LPS-
and CD40-induced production of IL-12, and in LPS-induced production of IL-1, these
cytokines production are still SB203580 sensitive. IFN-g production following
immunization with protein antigens and in vitro differentiation of naive T cells is greatly
reduced. RNAse protection assays show that only IL-12 mRNA level is decreased in
LPS-treated macrophages. Report assays confirm that regulation of IL-12 production is
at least partly at the transcriptional level (Lu et al., 1999).
So, p38 pathway regulates cytokines gene expression and controls cytokines production.
Mostly these regulations are on the transcriptional level, while IFN-g and TNF-a are
also affected at the post-transcriptional level.
6.2 Other Gene Expressions
(1)   IE Genes
p38 MAPK pathway regulates some immediate early gene expression. Activation of the
p38 signalling pathway has been linked to activation of Elk-1 ternary complex factor,
which binds to the c-fos promoter (Whitmarsh et al., 1997). In monocytic cells, LPS
increases the transactivation activity of MEF2C through p38-catalysed phosphorylation.
Activation of MEF2C increased c-jun gene transcription. This indicated that p38 may
influence host defence and inflammation by maintaining the balance of c-Jun protein
consumed during infection (Han et al., 1997b).It has been also reported that GnRH-
induced p38 MAPK activation may selectively contribute to the regulation of c-fos
protooncogene expression in aT3–1 cells (Roberson et al., 1999). Echovirus 1 (EV1)
infection increases the mRNA levels of cellular IE genes in host cells. p38 was the main
inducer of junB expression, whereas both p38 and ERK pathways were involved in the
induction of c-fos (Huttunen et al., 1998).
(2)   VCAM-1: (endothelial adhesion molecule vascular cell adhesion molecule-1)
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In human umbilical vein endothelial cells, SB203580 suppressed the TNF-a-induced
surface expression of the endothelial adhesion molecule vascular cell adhesion molecule
(VCAM)-1. The VCAM-1 mRNA accumulation was not affected by SB203580, this
suggested that the p38 MAPK pathway regulates the expression of VCAM-1 at the post-
transcriptional level (Pietersma et al., 1997).
(3)   iNOS: (inducible nitric oxide synthase)
The iNOS converts the L-arginine to L-citrulline and nitric oxide (NO). NO production
is directly correlated with iNOS activity and its expression. The promoter region of
iNOS has been characterized in murine with RAW 246.7 macrophage cell line.
Sequence analysis showed that this region contains several transcription factor binding
sites: NF-kB, AP-1, IFN-g response elements(g-IRE), g-activated site (GAS), IFN-g
stimulated response element (ISRE), TNF-a responsive element, among others (Xie et
al., 1993; Lowenstein et al., 1993; Xie et al., 1994; Nathan et al., 1994). Reporter assay
showed that AP-1 motif is not implicated in LPS-induced iNOS expression, but kB
motif is. After stimulation, NF-kB translocates to the nucleus and is bound to the
promoter of iNOS in rat hepatocytes in primary culture (Diaz-Guerra et al., 1996).
TNF-a plus IFNg elicited a strong enhancement of nitric oxide synthesis. Western blot-
and RT-PCR-experiments showed that these two cytokines together induce the
expression of iNOS. The induction of iNOS could be inhibited by SB203580. This
suggested that p38 pathway may  play an important role in regulating the induction of
iNOS gene expression in cytokine-treated cells (Bhat et al., 1999).
Full activation of the human iNOS (hiNOS) promoter by cytokines required downstream
and upstream NF-kB and AP-1 transcription factor binding sites. The combination of
LPS and IFN-g, but neither alone, increased hiNOS promoter activity 28-fold. p38
MAPK and ERK pathways by regulating the binding of AP-1 to specific promoter
sequences activate the promoter of hiNOS (Kristof et al., 2001).
(4)   COX-2: (cyclooxygenase-2)
COX-2 converts arachidonic acid to the endoperoxide intermadiate PGH2, which is
subsequently converted to prostaglandin (PEG2) by the action of cell specific
synthetases. In rat renal mesangial cells, IL-1b-induced COX-2 expression and PEG2
production depends on both JNK and p38 MAPK (Guan et al., 1998)
LPS induced the expression of COX-2 protein and COX-2 mRNA as well as the
phosphorylation and activation of ERK2 and p38 MAPK in monocytes. Since the
induction of COX-2 mRNA and COX-2 protein was inhibited by the specific inhibitors
of ERK and p38 MAPK, suggesting that the activation of ERK2 and p38 MAPK is
involved in COX-2 expression (Niiro et al., 1998).
It has also been found that p38 MAPK cascade plays a role in the transcription and
stabilization of COX-2 mRNA. IL-1 stimulated COX-2 transcription about 2-fold in
HeLa cells. In the cells previously stimulated with IL-1, SB 203580 treatment caused
rapid destabilisation of COX-2 mRNA (Ridley et al., 1998). Further experiments
demonstrated that p38 MAPKs were essential for stabilizing COX-2 mRNA in human
monocytes: when cells stimulated for 4 h with LPS were treated with actinomycin D,
PDF created with FinePrint pdfFactory trial version http://www.fineprint.com
39
COX-2 mRNA decayed slowly. Treatment of stimulated cells with 2 µM SB 203580
caused a rapid disappearance of COX-2 mRNA, even with actinomycin D present (Dean
et al, 1999). Other components of p38 MAPK cascade, MKK6, MK2 and maybe Hsp27,
were also found to be involved in the stabilization of COX-2 mRNA in Hela cells (Lasa
et al., 2000). Further experiment showed that Dexamethasone destabilizes COX-2
mRNA by inhibiting p38 MAPK (Lasa et al., 2001).
6.3   Apoptosis
Apoptosis is a common cellular response to stress and ample evidence showed that
activation of p38 pathway correlated with apoptosis. p38 pathway has been shown to be
involved in cell death induced by NGF withdrawal in PC12 cells (Xia et al., 1995;
Kummer JL et al, 1997), by ceramide in U937 and BAE cells (Verheij et al., 1996), by
anti-IgM antibody in human B lymphocytes (Graves et al., 1996), and by Fas-ligation in
Jurkat cells (Juo et al., 1997). In cultured chick fetal forebrain neurons, p38 activity was
down-regulated by insulin, which can support survival of these cells (Heidenreich and
Kummer, 1996). It has also been reported that thrombospondin-1 (Jimenez et al., 2000),
oxidative stress, TNF-a and TL-1, a TNF-like cytokine (Yue et al., 1999), induce a p38-
dependent apoptosis or signalling in endothelial cells.
Vascular endothelial growth factor (VEGF) is capable of eliciting biochemical responses
that either enhance cell survival by PI3-kinase/Akt pathway or might lead to cell death
by p38 MAPK pathway. Blockade of PI 3-kinase or Akt signalling attenuates
VEGF-stimulated MEKK3 phosphorylation and increases p38 signalling, thus
enhancing apoptosis. On the other hand, overexpression of constitutively active Akt
enhances MEKK3 phosphorylation and down-regulates p38 activation (Gratton et al.,
2001). Recently it has been reported that ERK-1/2 and p38 MAPK oppositely regulate
NO-induced apoptosis of chondrocytes. NO-induced p38 MAPK functions as an
induction signal for apoptosis and in the maintenance of chondrocyte phenotype,
whereas ERK activity causes dedifferentiation and operates as an anti-apoptotic signal
(Kim et al., 2002).
Though p38a is activated in Jurkat T cells during Fas ligation, its activity is not required
for apoptosis (Juo P et al, 1997). While other evidence showed that SB203580 do block
the apoptosis in serum depletion induced Rat-1 cell death (Kummer et al., 1997), NGF
withdrawal-induced PC12 cell apoptosis (Kummer et al., 1997) and TL-1-induced
bovine pulmonary artery endothelial cells apoptosis (Yue et al., 1999). So the role of
p38 MAPK pathway in apoptosis is cell type- and stimulus- dependent.
6.4   Cell Growth and Differentiation
p38 pathway is also involved in controlling cell growth and differentiation. Cdc42Hs, a
member of Rho family, activated p38a in NIH-3T3 cells. The activation of p38a can
inhibit serum-stimulated cell cycle progression at G1/S transition point (Molnar et al.,
1997). The p38a was activated in mammalian cultured cells when the cells were
arrested in M phase by disruption of the spindle with nocodazole (Takenaka et al.,
1998).
p38 MAPK pathway plays an important role in cell differentiation in several cell types.
The differentiation of PC12 cells into neurons (Morooka et al., 1998) and 3T3-L1 cells
into adipocytes (Engelman et al., 1998) both need p38a and or p38b, since SB203580
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can inhibit the effect. It has been found that p38 MAPK pathway is involved in
regulating chondrocyte differentiation. Parathyroid hormone (PTH) inhibites p38
MAPK and the inhibition converts a hypertrophic cell phenotype to a prehypertrophic
one (Zhen et al., 2001).
Table 1-12: Some cell lines mentioned in the introduction
____________________________________________________________________
Cell line Cell type or origin
____________________________________________________________________
RAW 264.7 murine macrophage cell line
C2C12 muscle cell line
CT6 murine cytokine-dependent T cell line
L929 mouse fibrosarcoma cell line
MEF mouse embryonic fibroblast




H19-7 hippocampal progenitor cells
____________________________________________________________________
THP-1 human monocytic cell line
Mono Mac  6 cells human monocytic cell line
HL-60 cell line human promyelocytic leukemic
PMNs human polymorphonuclear neutrophils
Hela human epithelial cell
HEK293 human embryonic kidney cell line 293
SH-SY5Y human neuroblastoma cells
A549 human lung epithelial cells
HUVEC human umbilical vein endothelial cells
SaOS2 human osteoblastic cells
___________________________________________________________________
BPAEC bovine pulmonary artery endothelial cells
PC12 rat phaeochromocytoma cell line
COS green monkey kidney cells
___________________________________________________________________
Fibroblast growth factor (FGF)-2 induces bovine capillary endothelial cells to form
tubular growth-arrested structures in collagen gel cultures. Recently it has been reported
that p38 MAPK negatively regulates endothelial cell survival, proliferation, and
differentiation in FGF-2-stimulated angiogenesis (Matsumoto et al., 2002). SB202190
can enhance FGF-2–induced tubular morphogenesis by decreasing apoptosis, increasing
DNA synthesis and cell proliferation, and enhancing cell differentiation. Whereas
overexpression of dominant negative mutants of the MKK3 and MKK6 also supported
FGF-2–induced tubular morphogenesis (Matsumoto et al., 2002).
PDF created with FinePrint pdfFactory trial version http://www.fineprint.com
41
II. MATERIALS and METHODS
1. Materials
The cell lines, mice, plasmid constructs, antibodies, oligonucleotides and some chemical
regents and equipments used in this study are listed in the tables below.
Table 2-1: Cell lines and mouse strains
______________________________________________________________________
Cell line/ Description Reference or source
mouse strain
______________________________________________________________________
MEF wt mouse embryonic fibroblast prepared by our group
MEF MK2 -/- MK2 deficient mouse prepared by our group
embryonic fibroblast
MEF MK5-/- MK5 deficient mouse prepared by our group
embryonic fibroblast
Hela cell human epithelial cell our group
ES cell E14-1 ES cell line provided by
Prof. Dr. Carmen Birchmeier
MK 5 Chimeras EMBL Heidelberg
C57BL/H199 Charles River
______________________________________________________________________
Table 2-2: Regents for cell culture
_______________________________________________________________________
Regent Description Reference or source
_______________________________________________________________________
DMEM Dulbecco's l modified Eagle's GibcoBRL, 31966-021
medium
NEAA nonessential amino acids GibcoBRL, 1140035
FBS fetal bovine serum Biochrom, S0115
FBS fetal bovine serum Sigma, F7524
   (especially for ES cells) (Lot. No. 77H3356)
T/E Trypsin/EDTA GibcoBRL, 25300-054
pen/strep    penicillin/streptomycin GibcoBRL, 05140-114
Lif (ESGRO)     prepared by our group
50 mM ß-ME    2-Mercaptoethanol GibcoBRL, 31350-010
Mitomycin C Sigma, M0503
G-418 sulate Geneticin Calbiochem, CN345810
Gelatin Sigma, G9391
______________________________________________________________________




Plasmid Description Reference or source
______________________________________________________________________






ptV-O “neo” vector provided by
Prof. Dr. Carmen Birchmeier
pSG5-myc-MK5-wt wt MK5 expression vector provided by
Dr. Ole Morten Seternes
pcDNA4- ko MK5 expression vector our group
-His-Max-MK5-ko
pEGFP-MK5 provided by




The oligonucleotides used in the experiments were all purchased from MWG.
Table 2-4: Oligonucleotides and their sequences
______________________________________________________________________
Oligos     Sequence Description
    (5’------3’)
______________________________________________________________________
Relevant sequence of MK5 gene (see
result, Fig 3-3)
MK5-RS-1833d    cgtaacactagccacagttgtaactga RS 1833-1859, 5’ primer
MK5-RS-2272d    gtaggccagcactgtgccaactgatgta RS 2272-2299, 5’ primer
MK5-RS-2830rc   catatacttgtaagcacagctctgagtt RS 2830-2803, 3’ primer
MK5 cDNA (AF039840)
MK5-1d  agttgaccaaggtgatttgatgaca MK5 cDNA 1228-1252, 5’ primer
MK5-2d  ggagaagtctggcatcatacctacctc MK5 cDNA 1315-1341, 5’ primer
MK5-1rc     ctggctccactcttcttctgggaactc MK5 cDNA 1522-1496, 3’ primer
MK5-2rc     gggatggtccaacactccctcgat MK5 cDNA 1612-1589, 3’ primer
MK5-707d  atgtcggaggacagcgacatggagaaag MK5 cDNA 707-235, 5’ primer
MK5-988d  cagggctcgactcttaattgtaatgg MK5 cDNA 988-1013, 5’ primer
MK5-1189rc    atctgcttttcaaggataactctctg MK5 cDNA 1189-1164, 3’ primer
(in the delete region)
MK5-1290rc  agtacctgaggtgctacatagtaagg MK5 cDNA 1290-1265, 3’ primer
MK5-2128rc  ctactggggctcgtggggaagggtctgc MK5 cDNA 2128-2100, 3 primer
ß-actin cDNA (X03672)
ß-actin-200d     ccagggtgtgatggtgggaatg ß-actin cDNA 200-221, 5’ primer
ß-actin-709rc     cgcacgatttccctctcagctg ß-actin cDNA 709-688, 3’ primer
______________________________________________________________________
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Table 2-5: Probes for hybridization
______________________________________________________________________
Probe Description Reference or Source
______________________________________________________________________
P1 external probe Bam HI-Sac I fragment, 1 kb
P2 internal probe Sac I fragment, 2.2 kb
P3 neo probe neo box, 1.2 kb
P4 internal probe Spe I-Bam HI fragment, 2 kb
P5 for NB MK5 CDS, cDNA 707-2128
______________________________________________________________________
Table 2-6: Antibodies, enzymes and chemicals
______________________________________________________________________
Ab/enzyme/Chemical Description Reference or Source
______________________________________________________________________
Anti-PRAK Upstate Biotechnology, 06960
PRAK substrate peptide             Upstate Biotechnology, 12-136
Anti-MK2 prepared by our group
Hyperfilm ECL for WB Amersham, RPN3103H
Hybond ECL  nitrocellulose Amersham, RPN303D
membranes for WB




p81 paper for kinase assay Whatman, 3698-915
Proteinase K Sigma, 2308
Restriction enzymes New England Biolabs
Taq DNA polymerase PCR GibcoBRL, 11508-017
T4 DNA ligase Cloning GibcoBRL, 15224-017




Lipopolysaccharides (LPS) Sigma, L8274
L-Histidinol Sigma, H6647
______________________________________________________________________




Kit Description Reference or source
______________________________________________________________________
Plasmid Maxi Kit QIAGEN, 12161
HotStarTaq polymerase PCR kit QIAGEN, 203205
QIAEX II gel QIAGEN, 20021
extraction kit
RNeasy mini kit QIAGEN, 74104
peqGOLD RNAPure FLTM extract RNA from cells peqLab, 30-1110
display THERMO-RT RT kit Display System Biotech
TOPO TA cloning kit Invitrogen, k4500-01
LipofectAMINE PLUS transfection kit GibcoBRL, 10964-013
Megaprime DNA probe labelling kit Amersham, RPN1604
labelling system
Cell Phect transfection kit Amersham, 27-9268-01
Bio-Rad Protein Assay protein concentration Bio-Rad, 500-0006
Mouse Immunoglobulin Panel Southern Biotechnology
Associates, 5300-01
Clonotyping System-HRP Southern Biotechnology
Associates, 5300-05




Equipment Description Reference or
source
______________________________________________________________________
Biometra TRIO-Themroblock PCR Machine Biotron (Germany)
CO2 UNITHERM 150 Incubator UNIEOUIP
Hybridzer
Bio-Rad Gene Pulser II Electroporation machine Bio-Rad
FUJIFILM BAS 1500 phosphoimager
______________________________________________________________________
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2. Methods
2.1   Construction of targeting vectors
2.1.1   Isolation of MK 5 genomic DNA
P1 Clone (P1+MK5 genomic DNA) was purchased from “Genome Systems” . The
plasmid was transferred from NS3529 to NS3516 via transduction and the DNA was
isolated according to the “P1 Manual”.
The MK5 genomic DNA and ES cell DNA were examined by PCR with primers, MK5-
1d, MK5-1 rc, MK5-2d and MK5-2 rc. 0.5 µg of MK5 genomic DNA or ES cell DNA
was used as a template to perform PCR in a 50 µl reaction volume: 1 × PCR buffer,
0.2 mM each dNTP, 0.2 µM Primers (1d+1rc; 1d+2rc; 2d+1rc or 2d+2rc),   2.5 units of
Taq DNA polymerase (GibcoBRL) with thermal-cycles including the first denaturation
at 96 oC for 3 min, 35 cycles of 96 oC  for 1 min, 60 oC  for 1 min and 72 oC for 3 min
and a final prolongation at 72 oC for 5 min.
2.1.2 Cloning of the 6.5 kb Bam HI and the 9 kb Sac I fragments of MK5 gene
2 µg of MK5 genomic DNA was digested by Bam HI or Sac I for 2h at 37 oC. The
digested DNAs were separated by 1% agarose gel. Then the two fragments, 6.5 kb
Bam HI fragment and 9 kb Sac I fragment, were extracted from the gel.
Ligations were accomplished at 16 oC in 20 ml reaction system, consisting of 1×ligation
buffer, 100 ng Bam HI fragment or 150 ng Sac I fragment, 40 ng cloning vector
pBS II KS(+) digested by Bam HI or Sac I respectively, and 1 unit of T4 DNA ligase
(GibcoBRL),  Then 1 µl of ligation mixture was used for transformation with 50 µl of
XL1 cell. Prior to inoculating, transformed bacteria were incubated at 37 oC for 1 h in
500 ml SOC (485 ml SOA +5 ml 1 M MgCl2 + 5 µl 1 M MgSO4 + 5 µl 2 M Glucose).
50 µl or the rest of  transformation mixture plus 40 µl of 50 mg/ml X-gal and 30 µl of
100 mM IPTG was finally spread on 1.5%-agar LB plate containing 50 µg/ml ampicilin
and incubated at 37 oC, overnight.
White colonies were picked up and the correct clones were determined by restriction
analysis after Miniprep procedure. The plasmids from Maxiprep were kept at –20 oC.
Scheme of pBluscript II KS(+):
B: Bam HI S: Sac I Spe: Spe I X:Xba I N:Not I Nh:Nhe I
                                S         N             X                Spe  B           Cla
---T7 promoter--------------------------------------------------------------------T3 promoter---
pBSIIKS(+): 3 kb
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Clone I: pBS II KS(+)+Bam HI fragment
                                      B1    S1            S2                      B2
     T7-----------                                        --------------T3
    6.5 kb Bam HI fragment
Clone II: pBS II KS(+)+Sac I fragment
                                 S2  Spe      B2                                       B3 S3 Spe
      T7------                                                         ---------T3
            9 kb Sac I fragment
2.1.3 Construction of the targeting vectors
(1) Construction of the 1st targeting vector
The subcloning procedure was similar to the cloning procedure described above.
Construction of the targeting vector included three main steps. After step (a), the clones
could not be selected by X-gal and IPTG.
(a) Construction of Clone-B6k
Subcloning 6 kb-Bam HI-fragment from Clone II into pBS II KS(+)
4 µg of Clone II was digested by Bam HI for 2 h at 37 oC, then the digested DNA was
separated by 1% gel. The 6 kb Bam HI fragment was extracted from the gel and was
inserted into the same sites (Bam HI sites) of a new pBS II KS(+) vector (Clone-B6k).
                                 S2  Spe     B2                                        B3 S3 Spe
      T7------                                                         ---------T3
         9 kb Sac I fragment
         Clone II
                    B3 B2
     T3------------------ ------------T7
             6 kb Bam HI fragment
         Clone-B6k
(b) Construction of Clone-NEO-B6k
inserting the “Not I-neo-Nhe I” box into the Clone-B6k by Not I / Xba I site
The neomycin-resistance gene (neomycinphosphotransferase) was got from ptV-O
which contained thymidine kinase (TK) promoter.
1.2 µg ptV-O vector was digested by Not I and Nhe I for 2 h at 37 oC, then the 1.2 kb
“neo” box fragment was extracted from the gel.
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           Not I --- Stu I- Xba I -Xho I---- neo   ---Bam HI- Hpa I---Nhe I
  1.2 kb
Clone-B6k was digested by Not I and Xba I for 2 h at 37 oC. To get Clone-NEO-B6k,
100 ng of the “Not I-neo-Nhe I” box fragment was inserted into 50 ng Clone-B6k,
linearized by Not I and  Xba I (compatible end with Nhe I ).
    B2                                        B3
       T7--Not I- -neo    -(Xba I/Nhe I)---       -------T3
                                    1.2 kb       6 kb Bam HI fragment
 
Clone-NEO-B6k
(c) Construction of the 1st targeting vector ( 1st TV).
inserting the 2.2 kb Sac I fragment of  Clone I into Clone-NEO-B6k through Sac I
sites
2 µg of Clone I was digested by Sac I for 2 h at 37 oC. To get the 1st targeting vector, the
2.2 kb Sac I fragment was extracted from the gel and inserted into the Clone-NEO-B6k,
which was linearized by Sac I.
                                       B1   S1            S2                    B2
     T7-----------                                        ---------------------T3
    6.5 kb Bam HI fragment
                Clone I
                  S1             S2                                B2                              B3
 T7---              --N-- neo  --X(/Nh)--                         -------------T3
2.2 kb          1.2 kb                        6 kb
                                                            1st TV
As described above, the 1st TV has a neo-box (1.2 kb) which was inserted between two
arms, a short arm (2.2 kb Sac I-F) and a long arm (6 kb Bam HI-F).
(2) Construction of the 2nd targeting vector
(a) Construction of Clone-S2,2k
      Subcloning 2.2 kb-Sac I-fragment from Clone I into pBS II KS(+)
2 µg of Clone I was digested by Sac I for 2 h at 37 oC. The digested DNA was separated
by 1% gel. The 2.2 kb Sac I fragment was extracted from the gel and was inserted into
the Sac I sites of a pBS II KS (+) vector (Clone-S2,2k).
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                                       B1   S1          S2                      B2
     T7-----------                                        ---------------------T3
    6.5 kb Bam HI fragment
                Clone I
       S1           S2
    T7-----------------    -      ----Not I---Xba I---Spe I------T3
                       2.2 kb
                                                      Clone-S2,2k
(b) Construction of Clone-S2.2k-NEO
inserting the “Not I-neo-Nhe I” box into the Clone S2.2k by Not I site and Xba I site
Clone-S2.2k was digested by Not I and Xba I for 2 h at 37 oC. To get Clone-S2.2k-
NEO, 100 ng of the “Not I-neo-Nhe I” box fragment (the same fragment as used in the
1st TV) was inserted into 50 ng Clone-S2.2k, linearized by Not I and Xba I.
      S1             S2
    T7-----    ------N- neo   --X(/Nh)-Spe I--------------------------T3
        2.2 kb           1.2 kb
Clone-S2.2k-NEO
(c) Construction of  the 2nd targeting vector ( 2nd TV)
inserting the 8 kb Spe I fragment of  Clone II into Clone-S2.2k-NEO through Spe I
sites
2 mg of Clone II was digested by Spe I, for 2h at 37 oC, and then the digested DNA was
separated by 1% gel.  To get the 2nd TV, the 8 kb Spe I fragment was extracted from the
gel and was inserted into the Clone-S2.2k-NEO, linearized by Spe I.
                                       S2  Spe                                                       S3 Spe
      T7------                                                         ---------T3
            9 kb Sac I fragment
         Clone II
                                      Spe                                                          Spe
            ----                                                   --------
 8 kb Spe I fragment
             
                           S1            S2                                   Spe                                                           Spe
T7------------     --N--- neo  --X(/Nh)---     ---------
T3
     2.2 kb             1.2 kb                        8 kb
                                                            2nd TV
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As described above, the 2nd TV has a neo-box (1.2 kb) which was inserted between two
arms, a short arm (2.2 kb Sac I-F) and a long arm (8 kb Spe I-F).
2.1.4   DNA analysis
DNA was isolated by plasmid Minipreparations (Sambrook, Fritsch and Maniatis:
Molecular Cloning, second edition, small-scale preparations of plasmid DNA, Section
1.25) and plasmid Maxipreparations according to the instruction of Plasmid Maxi Kit
(QIAGEN). DNA was analysed by restriction analysis, sequencing and Southern Blot
hybridisation.
(1) Sequence
7.5 µg DNA from Maxipreparation was sequenced with primer T 3, T 7 or custom
primers in the “DNA-Service-Labor, Biozentrum der Martin-Luther Universität”. The
2.85 kb region of MK5 genomic DNA between the first Sac I site to Spe I site (S1-Spe)
has been sequenced and was named as MK5 relevant sequence (MK5-RS).
(2) Southern Blot Hybridization
3 to 5 µg DNA from Maxipreparation was digested with Bam HI or other restriction
enzymes, and subjected to Southern blot. After pre-hybridization with Rapid-hybr.
buffer for two hours, the membrane was hybridized with radioactive labelled probe (see
Table 2-5) in the same hybridization buffer at 65 oC, overnight. Then the membrane was
washed in 2 × SSC, 0.1% SDS at 65 oC for 30 min and 0.2 × SSC, 0.1% SDS at 65 oC
for 30 min. After 4 to 24 hours exposure, the imager plate was scanned on the
Phosphoimager machine (FUJIFILM BAS 1500).
2.2   Generation of MK5 knockout  mice
2.2.1   Culture of ES cells
E14-1 ES (embryonic stem) cells which were derived from the 129/Ola substrain were
the generous gift from Prof. Dr. Carmen Birchmeier. The feeder cells were neo-resistant
MEFs (mouse embryonic fibroblasts) harvested from embryos at day E 13 by our own
group.
(1)   Culture of MEFs
MEF media
DMEM 500 ml
FCS   80 ml
NEAA     6 ml
pen/strep     6 ml
The MEFs were cultured at 37 oC in a 10% CO2, 95% humidified CO2 incubator.
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(2)   Inactivation of  MEFs
Passage 4 of neo-resistant MEFs were growth arrested by mitomycin C treatment to
serve as feeder. Mitomycin C was added to the media and final concentration of
mitomycin C was 10 mg/ml. MEFs were treated with mitomycin C for 2 h at 37 oC, then
washed with PBS for three times. Once the MEFs were inactive they could be stored in
the incubator for up to 5 days before using as feeder.
(3) Culture of ES cells
ES media
DMEM 500 ml
FBS   80 ml
NEAA     6 ml
Pen/strep     6 ml
Lif (ESGRO)     0.6 ml
50 mM ß-ME      1.2 ml
ES cells were grown on feeder layer in ES media at 37 oC in a 10% CO2 , 95%
humidified CO2 incubator. Passage 3 of ES cells were used for electroporation.
2.2.2   Preparation of the linearized targeting vector
150 µg Targeting vector (TV) was digested with 125 unit of Cla I in a 1.2 ml reaction
volume, at 37 oC for 2 h. Then the linearized TV was precipitated with ethanol and
redissolved in 80 µl water.
  Cla                S1            S2      B2                      B3       Cla
   ----T3-T7---            ---  neo  - --                                      -------
1st TV
           Cla             S1             S2                 Spe                                                  S3 Spe  Cla
                                                   
     ---T3-T7---           -- neo      --                                                            ------
                                                2nd TV
2.2.3   Electroporation and Selection of the ES cells
(1)   Trypsinizing the ES cells
10 cm-dish ES cells were washed with 10 ml PBS for three times and then were
trypsinized with 0.5 ml Trypsin/EDTA and PBS mixture (T/E:PBS=1:1), the dish was
put in the incubator at 37 oC for 3 min. Then the ES cells were gently disassociated with
a 1 ml pipette by carefully pipetting. The cells were checked under a microscope to
verify that single cell suspension was formed.
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ES cells were washed with PBS and harvested in a new tube. The cell pellet was
resuspended in 1 ml PBS. 25µg linearized targeting vector was added into half of the 10
cm-dish ES cells (in 0.5 ml volume). The cell suspension with the linearized TV was
kept in the hood for 10 min at room temperature. Half of 10 cm-dish ES cells were
spread on four 15 cm-dishes feeder after electroporation.
(2)   Electroporation
The ES cell suspension with linearized targeting vector was loaded into a 0.5 ml cuvette.
Electroporation was carried out using a Bio-Rad Gene Pulser II at a capacitance of 500
microfarads, and at 240 V/cm voltage. After electroporation, the cells were kept on ice
for 30 min and then were plated equally on the prepared four 15 cm-dishes feeder and
were kept in the incubator.
(3)   Selection of the ES cells
The electroporated cells were cultured under the same conditions as normal ES cells
(2.2.1-(1)). G-418 was added to the culture media 24 h to 36 h after electroporation.
Clones were selected for resistance to 385 µg/ml G-418. The media was changed daily
for the next 5 to 7 days, 20 ml of fresh ES selection media /15 cm-dish/day.
2.2.4 Picking the clones
The clones were picked after 7 to 8 days after electroporation.
(1)  96-well plates were prepared with feeder one day before picking clones. One 15 cm-
dish MEF feeder cells would provide for four 96-well plates.
(2) A microscope was placed into the hood and the UV light was turned on for at least
30 min.
(3) A 96-well plate was prepared with T/E, 50 µl /well.
(4) The media of the 15 cm-dish with ES clones was aspirated and the cells were
washed twice with PBS. 20 ml fresh DMEM without FBS and other regents was
added into the dish.
(5) The lid of the dish has been removed and the clones were picked with a 50 µl pipette
under the microscope.
(6) Each individual clone has been picked and was placed into the individual wells with
50 µl T/E for about 20 min.
(7) The clone was disaggregated by carefully pipetting and was transferred to one well
of a 96-well plate that already covered feeder layer and 150 µl ES media. 6 h later,
the media was aspirated and each well was feeded with 200 µl fresh ES selection
media.
(8) The cells were cultured in the presence of selection media under the same conditions
as normal ES cells, the media was changed everyday.
2.2.5 Freezing ES clones
The ES cells were cultured in 96-well plate for about 5 to 8 days (depending on how
large the clone was), then the cell clusters were dissociated with T/E+PBS and the cell
suspension was divided into halves. One half was frozen and the other half was plated
on gelatin-coated 48-well plate. The latter cells were allowed to grow (5 to 7 days) to
confluence and were used as the initial material for the DNA extraction procedure.
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(1)   Preparation of gelatin substratum plate: 0.5 ml of 0.1% autoclaved gelatin was
placed on each well of  a 48-well plate. Having stood in the 37 oC incubator for
more than 2 h, the gelatin was aspirated and the plate was dried in the hood.
(2)   Preparation of the 25% DMSO freezing media for ES cells:
DMSO: FBS (for ES cells)=1:3
(3)   Freezing ES cells: The ES media was aspirated from the well and the ES cells were
washed with PBS for three times. 60µl T/E and PBS mixture (T/E:PBS=1:1) was
placed into each well. Then the plate was put into a 37 oC incubator for 3 min. The
ES cells were disassociated by carefully pipetting and then 30µl of cell suspension
(half of the well) was transferred into a freezing cuvette which contained 30 µl ES
freezing media (finally the ES cells were in 12.5% DMSO solution) and the ES
cells were frozen slowly.
(4) The other half of ES cells (30µl) was cultured on gelatin-coated 48-well plate for 5
to 7 days.
2.2.6 Screening of the clones
(1) Isolation of genomic DNA from ES cells:
The other half of ES cells were cultured on gelatin-coated 48-well plate for 5 to 7 days,
then the cell lysis was carried out as follows: the cells were washed twice with PBS, and
300 µl of lysis buffer was added per well.
The lysis buffer: 10 mM NaCl
10 mM Tris.Cl (pH 8.0)
25 mM EDTA
0.5% SDS
1 mg/ml Proteinase K (added freshly)
The plates were incubated overnight at 55 oC with lightly shaking, then 300 µl of
phenol/chloroform was added (1 × vol ). The plates were centrifuged at full speed at
room temperature for 2 min and the upper phase was transferred to a new tube. 150 µl
7.5 M ammonium acetate (0.5 × vol) and 600 µl 100% cold ethanol (2 × vol ) were
added. After centrifugation at full speed for 10 min, the supernatant was discarded by
inversion of the plates and the precipitated was washed twice with 70 % ethanol. The
plates were left tilted to air dry for 30 min. The DNA was redissolved in 30 µl TE
buffer.
(2)   Screening the clones by Southern Blot Hybridization (see 2.1.4 (2))
25 µl of genomic DNA from step (1) was digested by Bam HI, and subjected to
Southern blot. The membrane was hybridized with radioactive labelled probe. The
experimental procedure was similar to the method of Southern Blot Hybridization above
(see 2.1.4 (2))
2.2.7 Preparation of positive clones for microinjection
Rescue the positive clones: The positive clones were thawed very quickly in the 37 oC
water bath and the cells were rescued in a 48-well plate with feeder layer. The 60 µl cell
suspension was transferred to one 48-well with 500 µl ES media. 6 h later, the first
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media was changed. ES cells were kept in a healthy, rapidly dividing state and the ES
media was changed everyday. The passage 4 to 6 of healthy ES cells were frozen.
Microinjection was done with passage 5 or 6 healthy ES cells. The targeted ES cells
were injected into C57BL/6J blastocyts by EMBL-Heidelberg Transgenic Service.
2.2.8 Generation of MK5 knockout  mice
(1) The male chimeric mouse was bred with femal chimeric mouse or with female
C57BL mouse to get brown mice (F1).
(2) The brown mice were genotyped by PCR and SB.
The brown MK5 +/- mice were bred to get knockout mice (MK5-/-) (F2).
2.2.9 Establishment of MK5 deficient embryonic fibroblast cell line (MK5-/-MEF)
(1)  Preparation of mouse embryonic fibroblast cells from MK5-deficient mice
MEF cells were prepared from five E13.5 embryos obtained by intercrossing MK5
ko homozygous (-/-) mice. The brain, heart and other organs had been removed and
the embryos were cut into small pieces and were treated with 0,5% Trypsin for 30
min. The MEFs had been harvested and finally plated on 15-cm culture plates. The
MEFs were grown in DMEM medium containing 10% FBS and 1% pen/strep at
37°C in a humidified atmosphere of 5% CO2.
(2)  co-transfection of pSV40 and pREP8 vectors to the MEFs
After few passages, the cells were transfected with pSV40 and pREP8 vectors using
Lipofectamin transfection Kit (LipofectAMINE PLUS, GibcoBRL). After 48 hours
of transfection, histidinol was added to the medium (final concentration was 3 mM)
to select the transfected cells.
Five days later, some clones could be seen. The clones were picked into 24-well
plate and were cultured with histidinol for two more days. The cells were grown
and expanded under the conditions above. Then the immortalized MK5 ko MEF
cell line has been established.
2.3 Genotype of the mice
2.3.1 Isolation of genomic DNA from mouse tails
(1) 4-5 mm of mouse tail has been cut and was put into 250 µl extraction buffer.
extraction buffer : 100 mM NaCl
50 mM Tris.Cl (pH 8.0)
25 mM EDTA
1% Triton X-100
(2) 50µl of Proteinase K (1 mg) was added and the tail was incubated in the 300µl
solutions at 55 oC overnight.
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100 mg dry Proteinase K (Sigma, 2308)
4.75 ml H2O
0.25 ml 1 M Tris pH 8.0
5 µl CaCl2
(final concentration 20 mg / ml, 1 mg/50 µl, store at 4 oC)
(3) 300 µl (1 × vol) of Tris pH 8.0 equilibrated phenol was added. The solution was
mixed vigorously and the centrifugation was performed at full speed at room
temperature for 2 min.
(4) The aqueous phase was transferred to a fresh tube, an equal volume of
chloroform/isoamyl alcohol (49:1) was added to the aqueous phase. After
centrifugation at room temperature for 2 min. The aqueous phase was removed to
a fresh tube.
(5) 150 µl (0.5 × Vol) 7.5 M ammonium acetate (NH4OAC) and 375 µl (1.5 × Vol)
isopropanol were added. The DNA was precipitated by centrifugation at room
temperature for 5 min. The pellet was washed once with 70 % ethanol.
(6) After air-dry, the pellet was redissolved in 30 µl TE buffer and was kept at –80 oC.
2.3.2 Genotype mice by PCR
0.8 µl of genomic DNA (ca. 200 ng) from mouse tail was used as a template to perform
PCR in a 25 µl reaction volume (HotStarTaq Kit, QIAGEN): 1 × PCR buffer, 0.2 mM
each dNTP, 0.2 µM Primer MK5-RS-1833d (5’ primer) and Primer MK5-RS-2803rc (3’
primer), 1 unit of HotStarTaq polymerase with Biometra TRIO-Themroblock (Biotron,
Germany).
The PCR programme: first denaturation and hot start at 96 oC for 15 min, 35 cycles of
96 oC for 1 min, 60 oC for 1 min and 72 oC for 2 min and 30 sec and a final prolongation
at 72 oC for 5 min.
2.3.3 Genotype mice by Southern Blot
25 µl of genomic DNA from mouse tail was digested by Bam HI and subjected to
Southern blot. The method was the same as above (see 2.1.4 (2))
2.4 Characterization of the mouse
2.4.1 Isolation of total RNA from tissues or from cells
(1) Isolation of total RNA from mouse liver, heart or spleen:
RNA isolation was based on the manual of RNeasy mini kit (QIAGEN). 150 to 200 mg
tissue was homogenized in 1600 ml RLT solution. After centrifugation at full speed at
room temperature for 3 min, the supernatant was transferred to a new tube. One volume
of  70% ethanol was added and mixed well. Mini columns were applied to 2-ml
collection tubes, about 700 ml volume was added to the mini column each time. After
centrifugation at full speed at room temperature for 1 min, the column was washed with
700 ml  RW1 solution by centrifugation as above. The column was washed with 500 ml
RPE solution by centrifugation at full speed at room temperature for 1 min for three
times.  Then the column was dried by centrifuging at full speed at room temperature for
2 min. 50 ml of DEPC water was added to the column and the RNA was harvested by
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centrifugation at full speed at room temperature for 1 min. The concentration of RNA
was measured and RNA was kept at –80 oC. 
(2) Isolation of total RNA from macrophages:
The total RNA of macrophages was isolated by using peqGold RNA Pure kit (peqLab).
5 ×106 cells were harvested in a tube, 1 ml peqGOLD RNAPureTM solution was added,
mixed well by pipetting. The mixed solution was kept at room temperature for 5 min,
then 200 ml chloroform was added. After vortex for 15 seconds, the solution was kept at
room temperature for another 10 min. After centrifugation at full speed at room
temperature for 5 min, the upper phase was transferred to a new tube. 500 ml
isopropanol was added and the solution was kept at room temperature for 15 min. The
RNA was precipitated by centrifuging at full speed at 4 oC for 10 min. The RNA pellet
was washed with 70% ethanol. After air-dry for 30 min, the RNA was re-dissolved in 50
ml DEPC water. RNA concentration was measured and RNA was kept at –80 oC.
(3)  RT-PCR
Reverse transcription (RT) was performed in a 20 ml consisting of 1 × display
THERMO-RT buffer, 0.5 mM each dNTP, 0.8 mg total RNA, 1 mM T25 primer, 2 ml
display THERMO-RT terminator mix. The reaction was carried out at 42 oC for 40 min,
stopped by at 65 oC for 10 min. The RT-solution was kept on ice for PCR or kept at
–80 oC until used.
PCR was carried out in 25 ml containing 1 × PCR buffer, 0.2 mM each dNTP, 0.2 mM
each primer, 1 ml RT-solution and 2 units of HotStarTag polymerase (QIAGEN) with
thermal-cycles including the first 96 oC for 15 min, then 35 cycles of 96 oC 1min, 50 oC
for 1min and 72 oC for 1 min, and a final prolongation at 72 oC for 5 min.
2.4.2 Western immunoblotting analysis
Proteins were extracted from the same amount of (0.2×105) cells and were resolved by
electrophoresis in 7.5-20% gradient polyacrylamide-SDS gels. Then the proteins were
transferred to nitrocellulose membranes (Amersham), incubated with blocking solution
(5% non-fat milk in 10 mM TrisCl and 150 mM NaCl) for 1 h, then probed for 22 h
with the 2 µg/ml of anti-PRAK (Upstate) in blocking solution at 4 oC. Washed with PBS
then the blots were subsequently probed with the rabbit anti-sheep HRP-conjugated IgG
(1:2000 dilution was used). The membranes were washed with PBS 20 min for three
times. Then the “Enhanced Chemiluminescence system” was used for detecting the
secondary antibody.  Blots were exposed to the film (Hyperfilm ECL).
2.4.3 MK5 Kinase Assay
(1) solutions for MK5 kinase assay
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50 mM Sodium Fluoride
5 mM Sodium Pyrophosphate
1% triton X-100
0.1% (v/v) b-Mercaptoethanol (add freshly)
Protease inhibitor cocktail (Roche, 1 tabet for 10 ml buffer, add
freshly)
    Substrate Buffer: 0.5 mM EGTA
0.5 mg/ml BSA
30 mM PRAK substrate (or 5-10 mg Hsp25 for 50 ml volume)
50 mM Tris-HCl (pH 7.5)
    Hot Buffer: 75 mM Mg Cl2
0.5 mM cold ATP
2 ml [g-33P]-ATP (fresh)
(2) protein extraction
Cells were washed with PBS, then lysed in 500 ml lysis buffer, after vortex for 10
seconds, the lysate was put on ice for 5 min. After centrifugation at full speed at
4 oC for 10 min, the supernatant was transferred to a new tube.
About 100 mg tissues were homogenized in 500 ml lysis buffer. The solution was
put on ice for 10 min. After centrifugation at full speed at 4 oC for 10 min, the
supernatant was transferred to a new tube.
The protein concentrations were determined with the “Bio Rad Protein
Determination Kit”.  400 mg (for Hela cells) or 1000 mg (for MEFs) proteins were
used per kinase assay.
(3) immunoprecipitation of MK5
Kinase was immunoprecipitated from the lysate by using 2 mg PRAK antibody
(Upstate) for 400 to 1000 mg proteins. After 1 h mixing at 4 oC, 30 ml  pre-
equilibred (in lysis-buffer) protein G-agarose (50% slurry) was added and mixed
for another hour.
The precipitate was washed 3 times with lysis buffer containing 0.5 M NaCl, two
times wash with 50 mM Tris-HCl pH 7.5.
(4) kinase assay
40 ml substrate buffer was added per assay. After preheating at 30 oC for 3 min,
10 ml hot buffer was added per assay. Kinase assay was performed at 30 oC for
20 min in 50 ml volume.
20 ml aliquot was spotted on Whatman p81 paper and washed extensively in 1%
phosphoric acid before counting
2.4.4 Induction of endotoxic shock
PDF created with FinePrint pdfFactory trial version http://www.fineprint.com
57
Administration of LPS and D-Galactosamine: LPS and D-Galactosamine were
purchased both from Sigma. The mice were challenged with intraperitoneal (i.p.)
administration of 1 µg of LPS and 20 mg of D-galactosamine or 10 µg of LPS and 20
mg of D-galactosamine. After administration, the experimental mice were observed for
24 h and the number and time of sacrificed mice were recorded.
2.4.5 Immunization
Sex-matched animals 6-12 weeks old were immunized by intraperitoneal administration
of 100 mg of human serum albumin coupled to DNP in incomplete Freunds adjuvant
(IFA). Serum samples were collected from the mice 10 days after primary immunization
or secondary immunization. Levels of DNP-specific immunoglobulin (Ig) isotype were
determined by ELISA using DNP-Albumin as a capture agent and goat anti-mouse
isotype-specific antibodies directly conjugated to alkaline-phosphatase (Southern
Biotechnology Associates). Anti-mouse Ig capture antibodies were used for the
measurement of non-specific antibodies level.
After immunization for 12 days, the mice were killed and the germinal centres in the
spleen were examined by histology. The centrocytes were stained by rhodamine-labelled
peanut agglutinin (PNA) and the B-cells were co-stained by FITC-B220-pan-B.
2.4.6 Measurement of cytokines production
The cytokines were determined with an ELISA kit (QuantikineTM, R&D Systems)
according to the manufacturer’s instructions by Chrite (in Berlin).
2.4.7 Statistical analysis
Differences between groups were analysed by t-test (SigmaPlot 4.0). A P value <0.05
was considered significant.
PDF created with FinePrint pdfFactory trial version http://www.fineprint.com
58
       III. RESULTS AND DISCUSSIONS
1. Analysis of MK 5 Gene and Construction of Targeting Vector
MAPK cascades transduce the signals from cell membrane to the nucleus and play
important roles on cell survival and adaptation. To learn more about MAPK functions, it
is very important to investigate the normal and pathophysiological functions in the
whole organism. In recent years, with the analysis of the mutant mouse strains produced
by gene targeting, we have gained new understanding about the functions of MAPK.
Some deficient mice on MAPK signal cascades have been produced. In p38 MAPK
cascade, MKK3 (Lu et al., 1999), p38a (Adams et al., 2000; Tamura et al., 2000), MK2
(Kotlyarov, 1999), ATF-2 (Reimold et al., 1996), partial and complete of CREB
(Bourtchuladze et al., 1994; Rudolph et al., 1998) and MSK1/2 (Wiggin et al., 2002)
deficient mice have been generated and analysed.
MK5 or PRAK (p38-regulated/activated kinase) was identified as serine/threonine
kinase phosphorylated by p38 independently by two groups in mouse and human
leading to the two different names (Ni et al., 1998; New et al., 1998). Meanwhile, it is
highly probable that PRAK is the human homologues of murine MK5.
Both MK2 and MK5 are direct downstream substrates of p38 MAPKs. MK5 displays
45% amino acid identity to MK2 (Ni et al., 1998). The phylogenetic tree (Fig. 3-1)
shows the phylogeny among six MAPKAPKs and the distances are related to the degree
of divergence between the sequences (Corpet, 1988). From this phylogenetic tree we can
see that the phylogenetic conservation between MK2 and MK3 is higher than that
between MK2 and MK5. This indicated that MK2 and MK5 may share diverse
functions, and their overlap functions are not as much as that between MK2 and MK3.
Since we already produced MK2 ko mice (Kotlyarov et al., 1999), therefore, to mutate
MK5 gene would be more important than to mutate MK3 gene by gene targeting. And to
produce MK5 ko mice would also help us to understand p38 MAPKs pathway more
clearly.
Fig. 3-1: Phylogenetic tree of six MAPKAPKs. 
The phylogeny of six MAPKAPKs (MSK1, MK1, MNK1, MK5, MK3 and MK2) are
showed in the figure. The phylogenetic conservation between sequences are related to
the degree of divergence of the sequence. D: tree root; PAM: distance between
sequences
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MK5 genomic DNA was isolated from a P1 clone obtained from “Genome Systems”.
Firstly, we examined the MK5 genomic DNA in P1 and ES cell DNA by PCR with
primers, MK5-1d, MK5-1 rc, MK5-2d and MK5-2 rc, which were designed according to
the MK5 cDNA (AF039840). Now we know that the primers are located in exon 7 to 10
of MK5 gene: MK5-1d in exon 7; MK5-2d in exon 8; MK5-1 rc in exon 9 and MK5-2
rc in exon 10 (Fig. 3-5; Table 3-1). With different combinations of these primers, we
obtained the same length PCR products both from ES cell DNA and from MK5 genomic
DNA (Fig. 3-2; Table 3-1 and Table 3-2). This indicated that the genomic DNA
contained MK5 cDNA sequence.
           M   1     2     3     4            1     2     3     4    M
         5 kb
        1.6 kb
 (a)     (b)
Fig. 3-2: Analysis of MK5 genomic DNA and ES cell DNA by PCR.
(a): PCR was performed using MK5 genomic DNA as template, with the primer
composition of No. 1 (MK5-1d and MK5-1rc), No. 2 (MK5-1d and MK5-2rc), No.3
(MK5-2d and MK5-1rc) and No.4 (MK5-2d and MK5-2rc); 2.5 kb, 5.5 kb, 1.7 kb and
4.5 kb PCR products were obtained respectively (indicated in Table 3-2). (b): PCR was
performed using ES cell DNA as template with the same primer composition of No. 1 to
No.4, the same length PCR products as in (a) were obtained. M: marker
Table 3-1: Location of primer
______________________________________________________________________
Primer Location (exon) Description
______________________________________________________________________
MK5 cDNA (AF039840)
MK5-1d 7 MK5 cDNA 1228-1252, 5’ primer
MK5-2d 8 MK5 cDNA 1315-1341, 5’ primer
MK5-1rc 9 MK5 cDNA 1522-1496, 3’ primer
MK5-2rc 10 MK5 cDNA 1612-1589, 3’ primer
______________________________________________________________________
Table 3-2: Results of PCR analysis of MK5 genomic DNA and ES cell DNA
______________________________________________________________________
No. Primer Composition PCR product
______________________________________________________________________
1 MK5-1d+MK5-1rc 2.5 kb
2 MK5-1d+MK5-2rc 5.5 kb
3 MK5-2d+MK5-1rc 1.7 kb
4 MK5-2d+MK5-2rc 4.5 kb
______________________________________________________________________
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By further analysis of the genomic DNA, we found that the P1 clone contains a 12.5 kb
MK5 genomic DNA. In this region, we could find at least five exons and some
restriction sites (Fig. 3-3). Very recently, we obtained a 163 kb MK5 genomic DNA
sequence from “Celera Genomics”. Analysing the sequence of this 163 kb genomic
DNA, we found that MK5 cDNA (AF039840) was mapped in a 15 kb region. This 15.5
kb region contains exon 2 to exon 14 of MK5 gene (MK5 cDNA 743-2128, the
sequence was not exact enough to detect the first exon of MK5 cDNA 707 to 742) and
some restriction sites. The 15.5 kb MK5 genomic DNA was shown in Fig. 3-5.
The 2.85 kb fragment between Sac I and Spe I (S1 to Spe, Fig 3-3) of P1 clone, has been
sequenced, named MK5 relevant sequence (MK5-RS, see Fig. 3-4) which contains two
exons of MK5 gene. MK5-RS 665 to 773 is identical with  MK5 cDNA 991 to 1099
which encodes catalytic subdomain IV of MK5; MK5-RS 1943 to 2032 corresponds to
MK5 cDNA 1100 to 1189 (90 bp) which encodes catalytic subdomains VI a and VI b of
MK5 (Fig. 3-4). Comparing the 15.5 kb MK5 genomic DNA structure to our 12.5 kb
MK5 genomic DNA (Fig. 3-3), we obtained the same structure and organisation of the
gene. Alignment of our 2.85 kb relevant sequence of MK5 with the 15.5 kb MK5
genomic DNA, we found that a 356 bp fragment in intron 4 was missed in our 2.85 kb
fragment (data not shown), this difference in sequences may be due to the difference in
mouse substrains used (E14-1 ES cells derived from 129/Ola mice).
Two targeting vectors were constructed according to the structure of 12.5 kb MK5
genomic DNA (Fig. 3-3). Before starting the electroporation, we checked MK5 genomic
DNA by Southern blot analysis with probe P2 and it was shown that MK5 gene was not
a multicopy gene (Fig. 3-6) so it is possible to mutate MK5 gene by gene targeting.
In our 2nd TV, an internal 0.8 kb Sac I–Spe I (S2-Spe, Fig 3-3) MK5 genomic fragment
was replaced by a neo cassette from ptV-O (Fig. 3-3). The deleted region encompasses
one exon encoding amino acids 131–161 of MK5, which contains a subdomain of the
catalytic region of MK5 required for protein kinase activity. With the 2nd TV, Southern
blot analysis of 300 independent G418-resistant clones revealed two clones, clone 60
and clone 149, which resulted from the desired homologous recombination event
(targeting frequency 0.6%) (Fig. 3-7). When hybridized with external probe P1 or the
internal probe P2, clone 60 and clone 149 both not only had the wild type 6.5 kb signal,
but also showed the 4.4 kb homologous recombination signal. Clones 56, 57 and 58 only
had the wild type signal and were shown for comparison. When hybridized with the 1.2
kb neo probe P3, clone 60 and clone 149 only had one 4.4 kb signal, while clone 56 had
a large fragment contained neo signal, clone 57 had four different signals which all are
larger than 4.4 kb and clone 58 had no neo signal. These results showed that the MK5
gene had been disrupted in clone 60 and clone 149 by homologous recombination and
that only one homologous recombination happened in the two positive clones. No
additional non-homologous integration events as seen for clones 56 and 57 could be
detected in these clones.
Unfortunately, we screened more than 1600 electroporated ES cell clones with the 1st
TV, but did not find any positive clones. The deleted region and the long arm were
different between the two TVs. The long arm of the 2nd TV is 8 kb, longer than the 1st
TV’s (6 kb). The deleted region in the 2nd TV is 0.8 kb, shorter than the deleted region
(3.3 kb (S2-B2, Fig 3-3)) in the 1st TV. That may be the reason for the higher
recombination frequency obtained with the 2nd TV.
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Fig. 3-3: Structure of MK5 gene and strategy applied to mutate the MK5 gene.
Structure and partial restriction map of MK5 gene, clone I (6.5 kb Bam HI fragment clone)
and clone II (9 kb Sac I fragment clone), two targeting vectors, targeted locus of the 2nd TV
and diagnostic probes. The MK5 sequence motifs encoded by different exons (shown by blue
boxes) are indicated (roman numerals, catalytic subdomains). The neo cassette was inserted
into the exon encoding subdomainVI; the mutant locus is expected to encode a truncated
kinase that lacks amino acids 131 to 161 of MK5, which are essential for enzymatic activity.
B: Bam HI; Cla: Cla I; E: Eco RV; Nh: Nhe I; N: Not I; S: Sac I; Spe: Spe I; X: Xba I. 1833d:
MK5-RS-1833d, 5’ primer; 2830rc: MK5-RS-2830rc, 3’primer; P: probe.
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TCGTCAGCCC TGGGGMATCT TAHNCATTTG CTCCCTTCCT CCACCATTAT  50
TTTGATTACT TTCTCTTTTC AAAAAATGTT TAAGGGCTTG GGGATTATAG
ATTAGTGATG GAGTGCTTGC CAACCGTACC TAAGGCCCTG GATTTACTCT
CTAATGCCCA GTGTGTGTGT GCGTGTGTGT AGTTAAAAGG AAAATAAAAC 200
ATTAAAGAGC CAGGTATAGT TGGTGCATGC CTATAATCCT AGCCCTTGAG
AAGCTGAGGC AGTGTCTCAG GCTTCGGGAA GTGCGCATGG GAAAGGGGGT
ACAGAAGCTG TGCTGGTAAA GCCAGTGGGA AGTCGATTGG GGTTCCCAAG
TGTGCTCTGA TGCTGAAAGC ATTTGGATGC AAGCAGAAGC ATTCATAGTC 400
CTAGTGGGAC TAGGAGGCAG AAGTTCATGT TTGGTTTTTT CTTTTTCTTC
CTTTTTACAT TTTGGTGGAG AATATGAGAG TCCTTGCACT TAGTTAGTGG
CTAGCTTACC CCGGACACAG TGGCTGCATA CTTTGTAGAT GACATCACTT
TAGGTCAGTG TTTGATGCTT CAGGGTTTTC CTTTTCCTTT TTTCCTTTGT 600
TTTTTTCCTT TTCCTTTTTT TTCTTTTTTT TTTAAACTTA ACAAAATCAA
ATGCTTTCAA ACAGGGCTCG ACTCTTAATT GTAATGGAGA TGATGGAAGG
GGGAGAGCTA TTTCACAGAA TCAGCCAGCA CCGGCACTTT ACAGAGAAGC
MAGCCAGCCA AGTAACAAAG CAGGCAAGTT GACCCCGGGT ACCCGGCCAA 800
ACTGCGACTA CCTTGTTAAG CAGTACAATT GCATTGTGGG AAGGGAAGCT
TAAAGAAAAG CTCCATTTGA CCTCTCATTG CCTGCTTTGT TATAATCAGA
AAGGAAGGAC ATCTTCCTAA AAGTGCCACT GACCCTTTAT ACTTTGGGAG
GGAGGATTGG ATTTTTAATT GCTTGTCACC TTTCCCAAGG ATGCTCTGAG      1000
AGTTTCCCCC ACGGTCTTAA CTGTGGACAG CTGTGGGCAG GTAGCATTTG
ATGCTGTTGC TATCACCTGA AAGACCTTCA GGCATTTGTA CCTAAGATGT
TTCTTGCATA AATCACCCAT CATTTCTGTG GGTTTTTGTA ATAGTGAGTG
ATTCTTGGTT ATATTCTATT TTATGTCCCA TACAATTNCC CTCATAGAGG      1200
TGACAGGCCT GTCTTCATAC CACGCADGTA GACCATAGGA AAGCDTGANG
CCACAACAGT TAGCATTGTG AGAAAGCTCG TCAGATTGTC CACCCTCTAT
TCTCTAGTGT CTCTGGATGC CYCCTTTCTG ATTGACTAGG GTTAACCACT
ATGTGAGTGC TGAGAAGATC CACAAGAGTT NGANGAACTA TTTAACTTTT      1400
AAATTACACC ATTCATTTTT CAACATTAAG ACTAAAGGAT GAGATGTGAC
CATCTGTAAA ATAAAAGCTG TCTCAGTCTA CACAGACAGA TGCATTTTCG
TGAGATAGGA AGTCAAGCTG GCTGGATGGA AGGTATTGCC TGCCATTCAG
CTCCTTAGGG TGCAGGTATC TGGAGGAGCA GCCCTGGGGT CACAGCAGGG      1600
GTCCACTNGG AAGCCCTTCT TATTGTGGAC TGCTGCCTCT GGGTCCCCAC
AGTACCTGTC ACAGCACAGG TAAAGGAGTG GCCAGGCATC TTACAGGATG
TGTCCACCGC TTTATTCTGA CAGAGGATCA TTTGTAGTCG TGCTTGTTCA
GTAAATATAG GTTATAGTTA AACTAAGGCC AATGTATTTG TGTTTCTTGG      1800
TGTCCCAAGT CTTTCTTAGT TTCTCTCGTG TACGTAACAC TAGCCACAGT
TGTAACTGAC TTAAACCCCT GAGCTCTCAC ACTAGGGGTG TTAGAGATGG
TGCTTTTCTA AGAGGTGGCT GGTCCACTGT GCCCTTTTCC AGATAGCCCT
GGCTCTACAG CACTGTCACT TGCTAAACAT TGCGCACAGA GACCTCAAGC      2000
CTGAAAATCT GCTTTTCAAG GATAACTCTC TGGTGAGAAC AACTGCTTTT
CCTCATTTGA TGCTGTCACT TTGTTTTGTT TTGTTCAGTT TCTGTTTTTT
AAAGATAGAG TCTGTCTATC CCAGGCCAGC CTTGAACTTA TTCTGTAGCT
GCAGATGTCC TCGATCTTCT GACCTCCTGC CTCCACCTCC TTTTGCGTGT      2200
TGGGATTCCA GGTATGCATC AGCAGACTCA GTTTATGTGA CTGTGGGGTT
GAATCCAGGG CTTCGCACCC AGTAGGCCAG CACTGTGCCA ACTGATGTAC
ATCCTCAGGC TGGTTTAATT TTTGCCATAC TGTCTTGCTT TGTGGACCAG
GCTGGCCCGG AACCCATGTA AACGAGGTTG GCCTAAAACT CAGGAAGCCT      2400
TTGCTTCCTG AGTGCTGGGA TTGCAAGTGT GTGCTTCCTG CTGCTGTACT
GACCCCGTGC ACAGGAGGTT NAGGCATGTG CTTCTAATAC TTCAGCGCCC
ACTCTTTCCT TGTTAGGGCC TCAGAACTGT TGCCACACCC ATGGCATGGG
TGATTTGGAT TGTACAGATA CATCTGTGGG GCTTATGAAC TTGCATATTA      2600
TCTGGACAGC CTTTGGGGAG AGGCAGGAAT TGACATGCTG TTACATAGTT
CAGTTAGAGT TGCTGTTAGC CCTGATATAG GCTGTGTTCT TTTCCTGGTT
TCCTGTCCAT ATTCAGTATA CTAGTCAGTT GCTCCAGTTG CCAGTYTTCA
GAGTGAGGCT GGGTGGATGA GAGGAGGGCC AGCCTGTTAG TTAAGACTCT      2800
GTAACTCAGA GCTGTGCTTA CAAGTATATG TCTGGGGGCT TGTKAGATKG
Fig. 3-4: Relevant sequence of the MK5 gene.
MK5-RS 665 to 773 (blue)= MK5 cDNA 991 to 1099, exon 5 which encodes catalytic
subdomain IV of MK5; MK5-RS 1943 to 2032 (red)=MK5 cDNA 1100 to 1189, exon 6 which
encodes catalytic subdomains VI a and VI b of MK5.
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Fig. 3-5: Structure of the 15.5 kb MK5 genomic DNA.
Structure and partial restriction map of the 15.5 kb MK5 genomic DNA. The MK5 sequence
motifs encoded by different exons (shown by blue boxes) are indicated (roman numerals,
catalytic subdomains). I-XI: MK5 catalytic subdomians; E 2-14: exon 2-14; In 2-13: intron 2-
13; S 1-6: 6 Sac I sites; B 1-4: 4 Bam HI sites; 1d: 5‘ primer, MK5 cDNA 1228-1252; 2d: 5‘
primer, MK5 cDNA 1315-1341; 1 rc: 3 ‘ primer, MK5 cDNA 1522-1496; 2 rc: 3‘ primer,
MK5 cDNA 1612-1589.
n  Bam Sac
   6.5 kb
    2.2 kb
Fig. 3-6: Southern blot analysis of mouse genomic DNA with probe P2.
The non-digested mouse genomic DNA (n) and the mouse genomic DNA digested by
Bam HI (Bam) or by Sac I (Sac) hybridized with 2.2 kb internal probe P2. No
positive signal could be detected in non-digested genomic DNA; one band at 6.5 kb
was detected in lane Bam, and one band at 2.2 kb was detected in lane Sac.
(The Bam HI fragment, Sac I fragment and probe P2 have been indicated in Fig. 3-3.)
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 Clone       60  149   56  57   58          60  149   56  57   58          60  149   56    57   58
6.5 kb
4.4 kb
       A   B C
Fig. 3-7: Southern blot analyses of the electroporated ES cell clones.
ES cell DNAs were digested by Bam HI and then were hybridized with 1 kb external
probe P1 (A), 2.2 kb internal probe P2 (B) and 1.2 kb neo probe P3 (C). For clone 60
and clone 149, two bands at 6.5 kb and 4.4 kb were detected in A and B, but only one
band at 4.4 kb was detected in C. For clone 56, 57 and 58, one band at 6.5 kb was
detected in A and B.  One large band was detected in clone 56 in C; and four different
bands which all are larger than 4.4 kb were detected in clone 57 in C; no signal was
detected in clone 58 in C. (The Bam HI fragments and the probes have been indicated
in Fig. 3-3.)
2. Generation and Characterisation of MK5-Deficient Mice
Chimeric mice were generated by injecting the targeted ES cells into C57BL blastocysts
by EMBL-Heidelberg Transgenic Service. 20 chimeric mice have been obtained from
the two positive clones (see Table 3-3). Both clone 60 and clone 149 resulted in
germline transmission of the disrupted MK5 allele. Heterozygotes (+/-) were
intercrossed to generate homozygous mutant mice (-/-) that were identified by PCR and
Southern blot analysis of genomic DNA.
Table 3-3: 20 chimeric mice. M: male; F: female




520787 24.09.00 M Clone 149 90%
520788 24.09.00 M Clone 149 90%
520789 24.09.00 M Clone 149 90%
520790 24.09.00 M Clone 149 80%
520791 24.09.00 M Clone 149 80%
520792 24.09.00 M Clone 149 70%
520793 24.09.00 M Clone 149 40%
520794 24.09.00 F Clone 149 100%
520795 24.09.00 F Clone 149 90%
520796 24.09.00 F Clone 149 80%
520797 24.09.00 M Clone 149 90%
520798 24.09.00 M Clone 149 30%
520799 24.09.00 F Clone 149 90%
520800 24.09.00 F Clone 149 90%
520801 24.09.00 F Clone 149 80%
520802 24.09.00 F Clone 149 70%
520803 30.09.00 M          Clone 60 90%
520804 30.09.00 M          Clone 60 50%
520805 30.09.00 F          Clone 60 40%
520806 30.09.00 M          Clone 60 90%
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The MK5 knockout mice were viable and fertile, grew to normal size and did not exhibit
obvious behavioural defects. The genotypes of 53 offspring from MK5 heterozygous
(+/-) mice intercrossing were examined and the mice were present at a frequency
consistent with Mendelian inheritance (Table 3-4).
Table 3-4: Birth rate of the mice

































































































of Mice +/+ +/- -/-
53 13 29 11
Ratio 1 2.2 0.8
(1) Screening and Genotyping of the Mice by PCR
Using primers MK5-RS-1833d and MK5-RS-2830rc, we screened mouse-tail DNA. The
PCR product of wt DNA was about 0.97 kb and the product of homologous
recombinated DNA was about 1.2 kb (Fig. 3-8). In Fig.3-8 (b), No. 13, 18 and 25 were
wild type mice (+/+); No. 14, 15, 16, 19, 20 and 28 were MK5 heterozygous mice (+/-);
No. 17, 21 and 34 were MK5 ko mice (-/-).
    (a)
                    B1   S1           S2                    Spe            B2                                                S3
                                                --- neo  --
        1833d   1.2 kb       2830 rc
                                                                               P4 (2kb)
         M   13  14   15  16   17   18  19  20   21   25   28  34
(b)
            1.6 kb                  1.2 kb
     0.97 kb
Fig. 3-8: Screening and genotyping mice by PCR.
(a): Structure of homologous recombination DNA, primers for PCR and 2 kb internal
probe P4. (b): Genotype of 12 mice. One band at 0.97 kb was detected in No. 13, 18
and 25; Two bands at 1.2 kb and 0.97 kb were detected in No. 14, 15, 16, 19, 20 and
28; and one band at 1.2 kb was detected in No. 17, 21 and 34. B: Bam HI; S: Sac I;
Spe: Spe I; M: Marker; 1833d: MK5-RS-1833d, 5’ primer; 2830rc: MK5-RS-2830rc,
3’primer; P4: Spe I-Bam HI fragment, 2 kb internal probe.
(2) Characterisation of the Gene Targeting Mice by Southern Blot Analysis
Mouse-tail genomic DNA were digested by Bam HI and hybridized with probe P4 (an
internal probe). The wt signal would be 6.5 kb and the homologous recombination
signal would be 2.0 kb (Fig. 3-3). Four mice had been genotyped by SB in Fig. 3-9.
No. 270, 251 only had 6.5 kb signal so they were wt (+/+); No. 234  had both 6.5 kb and
2.0 kb signals so it was a MK5 heterozygous (+/-) mouse; No. 232 only had 2.0 kb
signal so it was a MK5 ko (-/-) mouse.
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  232     234     270     251
6.5 kb
2.0 kb
Fig. 3-9: Southern blot analysis of the mice with probe P4.
Mouse-tail genomic DNA was digested by Bam HI then hybridized with 2 kb internal
probe P4. One band at 6.5 kb was detected in mouse number 270 and 251; two bands
at 6.5 kb and 2 kb were detected in mouse number 234; one band at 2 kb was detected
in mouse number 232.
(3) Characterisation of the Gene Targeting Mice by Northern Blot Analysis, RT-PCR
and Sequencing
We further characterized the mice on RNA level with Northern blot analysis and
sequencing RT-PCR products. Northern blot analysis using MK5 coding domain
sequence (MK5 cDNA 707-2128) as a probe (probe P5) detected transcripts both in the
total macrophage RNA of wt (+/+) and homozygous ko (-/-) mice (Fig. 3-10). This
indicated that the gene targeting does not affect the mutant DNA transcription. To
further analyse the total macrophage RNA, we applied RT-PCR with primers MK5-
707d and MK5-2128 rc or MK5-988d and MK5-2128 rc. As expected, the PCR
products of ko macrophage were about 0.1 kb shorter than the wt products (Fig. 3-11).




Fig. 3-10: Northern blot analysis of macrophages with probe P5.
Total macrophage RNA of wt (+/+) and MK5 ko (-/-) mice were hybridized with
probe P5 (MK5 coding domain sequence, MK5 cDNA 707-2128) (a) or b-actin (b),
one band was detected both in wt and MK5 ko mice in (a) and (b).
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M                      a       b                       c      d
   1.6 kb
   1.0 kb
Fig. 3-11: RT-PCR of macrophages
RT-PCR was performed using total macrophage RNA of wt mouse (b, d) or MK5
ko mouse (a, c), with the primer composition of MK5-707d and MK5-2128rc (a, b) or
MK5-988d and MK5-2128rc (c, d).  One band was detected in lane a, b, c and d. The
PCR product in a or c was shorter than that in b or d. M: marker
ATGTCGGAGG ACAGCGACAT GGAGAAAGCC ATCAAGGAGA CCTCCATTTT    50
AGAAGAATAT AGTATCAATT GGACTCAGAA ACTGGGAGCC GGAATTAGTG
GTCCAGTTAG AGTCTGTGTG AAGAAATCCA CTCAAGAACG GTTTGCACTG
AAAATTCTTC TTGATCGTCC AAAAGCTAGA AATGAGGAGC GCCTGCACAT  200
GATGTGTGCC ACACACCCCA ACATAGTTCA GATTATTGAA GTGTTTGCTA
ACAGTGTACA GTTCCCTCAT GAGTCCAGCC CCAGGGCTCG ACTTTTAATT
GTTATGGAGA TGATGGAAGG GGGAGAGCTA TTTCACAGAA TCAGCCAGCA
CCGGCACTTT ACAGAGAAGC AAGCCAGCCA AGTAACAAAG CAGGACGCCC  400
CTGTGAAATT ATGTGACTTT GGGTTTGCTA AAGTTGACCA AGGTGATTTG
ATGACACCCC AGTTTACCCC TTACTATGTA GCACCTCAGG TACTGGAAGC
GCAGAGACGG CACCAGAAGG AGAAGTCTGG CATCATACCT ACCTCGCCAA
CACCCTACAC TTACAACAAG AGCTGTGACT TGTGGTCCCT AGGGGTGATA  600
ATTTATGTGA TGCTGTGCGG ATATCCTCCT TTTTACTCCA AACACCATAG
TCGGACTATC CCAAAGGATA TGCGGAAAAA GATCATGACA GGAAGTTTCG
AGTTCCCAGA AGAAGAGTGG AGCCAGATCT CAGAGATGGC TAAAGATGTT
GTGAGGAAGC TTCTGAAGGT CAAACCAGAG GAAAGACTCA CAATCGAGGG  800
AGTGTTGGAC CATCCCTGGC TCAACTCGAC AGAGGCCCTG GATAATGTGC
TACCCTCTGC CCAGCTGATG ATGGATAAGG CGGTGGTTGC GGGGATCCAG
CAGGCGCACG CCGAGCAGCT GGCAAACATG AGGATCCAGG ACCTCAAGGT
CAGCCTCAAA CCCCTGCACT CTGTCAACAA CCCCATTCTC AGGAAGAGGA      1000
AGCTGCTGGG CACCAAGCCA AAGGACGGTA TTTATATACA CGACCATGAG
AATGGAACTG AGGACTCAAA TGTTGCCTTG GAAAAGCTTC GAGATGTCAT
TGCCCAGTGT ATCCTCCCCC AGGCTGGAGA GAATGAAGAT GAGAAGCTGA
ATGAGGTAAT GCAGGAGGCC TGGAAGTACA ACCGCGAATG CAAGCTCCTG      1200
AGGGATGCTC TGCAGAGTTT TAGCTGGAAT GGCCGTGGAT TCACAGATAA
AGTTGACCGA TTGAAGCTGG CAGAGGTGGT AAAGCAGGTG ATCGAAGAGC
AGACCCTTCC CCACGAGCCC CAGTAG      1326
Fig. 3-12: MK5 ko mice coding domain sequence
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Fig. 3-13: Alignment of MK5 protein sequences of wt and ko
The cDNA of MK5 ko macrophage was mutated by deleting MK5 cDNA of 1100-
1189 in the wt (AF039840). This exon deletion removed amino acids 131–161 of
MK5. Amino acid number 63 in wt was valine (V) while in ko was glutamic acid (E);
and another two more amino acids, lysine and glycine (K and G), number 407 and
408, were also missing in ko protein sequence.
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Cloning and sequencing of the PCR product of ko macrophage cDNA with primers
MK5-707d and MK5-2128 rc, we found that the cDNA of ko macrophage was mutated
by deleting MK5 cDNA of 1100-1189 in the wt which stands for exon 6. This exon
deletion removed amino acids 131–161, “IALALQHCHLLNIAHRDLKPENLLFK
DNSL”, which consist of the conserved kinase subdomain VI a and VI b. Since
subdomain VI b contains the catalytic region of MK5 required for protein kinase
activity, the ko mice should not have MK5 kinase activity. This was confirmed by the
kinase assays of MK5 later. After the deletion, MK5 ko coding domain sequence was
still in the reading frame (Fig. 3-13).  This could explain why we still detected the MK5
signal in ko mouse in Northern blot analysis using MK5 coding domain sequence as a
probe. There were another two more differences between the wt and ko MK5 protein
sequences: (1) Amino acid number 63 in wt was valine (V) while in ko was glutamic
acid (E). This maybe because of the mismatch of PCR, GTG (wt) to GAG (ko), which
stands for V or E. (2) another two more amino acids, lysine and glycine (K and G),
number 407 and 408 were also missing in ko protein sequence. This may result from the
individual difference between the two mice line.
(4)  Characterisation of the Gene Targeting Mice by Western Blot Analysis, Protein
Kinase Assay and Subcellular Localization
To determine whether the mutant mice still have MK5 kinase activity, we further
characterized the mice by Western blot analysis and kinase assay. MK5 ko MEFs were
prepared from five E13.5 day MK5 ko embryos. Proteins were extracted from the same
amount of (0.2 ×105) cells. Extracts of MEF and macrophage from wt (+/+) or MK5 ko
(-/-) animals were examined by Western blot analysis with a polyclonal antibody
directed against MK5 (anti-PRAK, Upstate). Anti-PRAK is a sheep immunoaffinity
purfied IgG which used a full length human PRAK as antigen, it also contains a
N-terminal hexa-histidine tag and was expressed in Sf 9 cells. The Western blot analysis
confirmed the absence of 54 KDa MK5 protein both in MEF and in macrophage of
MK5 ko animals (Fig. 3-14). From the sequence of RT-PCR product, we know that the
mutant MK5 protein was 30 amino acids shorter than the wt MK5 protein. The weak
lower molecular weight band could be detected in Western blot, which corresponds
probably the truncated kinase.
             wt1  M2       E1   E2   E3  E4  E5   A                               wt2   M5    A
       54 kDa                                                                                54 kDa
(a) (b)
Fig. 3-14: Western blot analysis
Extracts of MEF and macrophage from wt (+/+) or MK5 ko (-/-) mice were examined
with anti-PRAK antibodies (Upstate). 54 KDa signal was absent in E1 to E5 (a) and
M5 (b), but a weak lower molecular weight band could be detected in these lanes. wt1:
wild type MEF; M2: MK2 ko MEF; E1 to E5: MK5 ko MEF from 13.5 day embryo 1
to 5; A: A 431 cell lysate, positive control of MK5, 54 KDa; wt2: wild type
macrophages
PDF created with FinePrint pdfFactory trial version http://www.fineprint.com
71
In the next step, we analysed MK5 kinase activity. MEFs were stimulated by treatment
with 250 mM arsenite or 300 mM sorbitol for 60 min. Proteins were extracted from the
cells and kinase was immunoprecipitated from the cell lysates with anti-PRAK antibody
(Upstate). Kinase assays were performed using PRAK-substrate peptide (Upstate). Both
wild type and MK2 ko MEFs showed basal kinase activities, more than 1250 cpm, while
the kinase activity was hardly detected in MK5 ko MEF (protein kinase assays
demonstrated that the MK5 ko (-/-) MEF was deficient in MK5 activity (Fig. 3-15).) The
differences of kinase activity between wt MEF and MK5 ko MEF were significant
(P<0,01), but there were no differences of the kinase activity between all the stimulated
and non-stimulated MEFs (P>0,05) (Fig. 3-15).
Fig. 3-15: MK5 kinase assay in MEFs
MEFs were stimulated by treatment with 250 mM arsenite or 300 mM sorbitol for 60
min. Proteins were extracted from the cells and kinase was immunoprecipitated from
the cell lysates with anti-PRAK antibody (Upstate). Kinase assays were performed
using PRAK-substrate peptide (Upstate). The kinase activity was measured by
scintaillation. Wt: wild type MEF; MK2 ko: MK2 ko MEF; MK5 ko: MK5 ko MEF.
To confirm the experimental system for kinase assay works well, we performed MK2
kinase assays with the same cell lysates above and detected a very strong activation in
MK2 kinase assays (Fig. 3-16). The kinase assays were performed similar to the MK5
kinase assay. In this case we used 5ml anti-MK2 antibody (prepared by our group) to
immunoprecipitate MK2 from the same cell lysates (for MK5 kinase assay above). In all
non-stimulated MEFs, the kinase activity was very low, the signal was in range between
360 to 630 cpm. MK2 activity could be highly activated by arsenite or sorbitol both in
wt and MK5 ko MEFs. Stimulated by arsenite treatment for 60 min, MK2 activity
reached relative level of 8000 cpm in wt MEF and 15200 cpm in MK5 ko MEF. The
differences of the kinase activity between non-stimulated cells and cells stimulated by
arsenite were significant both in wt MEF (P<0,001) and in MK5 ko MEF (P<0,05).
After hyperosmotic treatment with sorbitol for 60 min, the relative kinase activity
reached 1190 cpm in wt MEF and 3600 cpm in MK5 ko MEF. In contrast, in MK2 ko
MEFs, neither arsenite nor sorbitol could activate the kinase and there were no
difference of the kinase activity between the stimulated and non-stimulated MK2 ko
MEFs (P>0,05) (Fig. 3-16).
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Fig. 3-16: MK2 kinase assay in MEFs
MEFs were stimulated by treatment with 250 mM arsenite or 300 mM sorbitol for 60
min. Proteins were extracted from the cells and kinase was immunoprecipitated from
the cell lysates with anti-MK2 antibody (prepared by our group). Kinase assays were
performed using PRAK-substrate peptide (Upstate). The kinase activity was measured
by scintaillation. Wt: wild type MEF; MK2 ko: MK2 ko MEF; MK5 ko: MK5 ko
MEF.
Fig. 3-17: MK5 kinase assay in transfected MEFs
Transfected MEFs were stimulated by treatment with 200 mM arsenite (ARS) for 45
min, Proteins were extracted from the cells and kinase was immunoprecipitated from
the cell lysates with anti-PRAK antibody (Upstate). Kinase assays were performed
using PRAK-substrate peptide (Upstate). The kinase activity was measured by the spot
density using the phosphoimaging. MK5-wt: MK5 ko MEF transfected with pEGFP
and pSG5-myc-MK5-wt expression vectors; MK5-ko: MK5 ko MEF transfected with
pEGFP and pcDNA4-His-Max-MK5-ko expression vectors.
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In order to determine the activator of MK5 and the function of mutant MK5 protein, we
co-transfected pEGFP and the pSG5-myc-MK5-wt expression vectors or pEGFP and
pcDNA4-His-Max-MK5-ko expression vectors to MK5 ko MEF and then measured the
MK5 kinase activities of the transfected cells. We obtained similar results in MK5
kinase assays. The transfection efficiency was reached to 60% in all experiments,
checked by fluorescence microscopy. Cells were stimulated by 200 mM arsenite for 45
min. MK5 was immunoprecipitated from the same amount of proteins as above with
anti-PRAK antibody (Upstate), then the kinase assays were carried out under the same
conditions as MK5 kinase assay described above. The kinase activity was measured by
the spot density using the phosphoimaging. The kinase activity of MEF transfected with
MK5-wt expression vector was about 370 and after stimulation, no significant difference
increase was detected (P>0,05). The kinase activity of MEF transfected with MK5-ko
expression construct was about 150 and after stimulation, no significant difference was
detected neither (P>0,05). The comparison of activities between the MEFs transfected
with MK5-wt and MK5-ko vectors, both in non-stimulated and stimulated by arsenite
cells, exhibits no significant difference (P>0.05) (Fig. 3-17). These results showed that
there were no activation of MK5 even in the transfected cells and the mutant MK5 had
no kinase activity.
Taken together, the results demonstrate that the targeted disruption of the MK5 gene
resulted in a null allele.
Subcellular localization of p38 MAPK and their downstream targets of p38 MAPKs
may show their different physiological functions in certain conditions. For mouse MK2,
two regulatory phosphorylation sites, T205 and T317, have been identified (Engel et al.,
1995). T205 is located in the kinase activation loop between subdomains VII and VIII
whereas T317 is outside the catalytic domain in a hinge region between the catalytic
domain and the C-terminal extension, which carries an autoinhibitory A-helix motif, the
nuclear export signal (NES) and the nuclear localization signal (NLS) (Engel et al.,
1998). Under control conditions, MK2 is present in the nucleus, and upon stimulation it
becomes phosphorylated by p38 and is consequently exported from the nucleus
probably due to unmasking of its NES. This translocation is blocked by SB203580 and
leptomycin B (LMB) (Ben-Levy et al, 1998; Engel et al, 1998). Interestingly, the
mutation T317E, but not T205E, resulted in a protein constitutively exported from the
nucleus and accumulated in the cytoplasm of the cell (Ben-Levy et al., 1998; Engel et
al., 1998). Hence, it is supposed that phosphorylation of T317 is the critical event for
parallel regulation of MK2 activity and localization.
The export and conformation of MK2 were also studied by fusion of green fluorescent
protein (GFP) variants to the N- and C-terminus. An expression plasmid EGFP-MK2-
EBFP (GMB) was constructed. It has been found that GMB is present in the nucleus of
non-stimulated Swiss 3T3 cells and translocates to the cytoplasm after stress stimulation
which reflects the major properties of wt MK2. When Crm1-dependent nuclear export is
blocked by LMB, GMB accumulates in the nucleus. Expressed GMB or the mutant
GMB-T317E in HEK293 cells and analysed by fluorescence resonance energy transfer
(FRET), it has been found that GMB exists in the closed (an inactive) conformation in
the nucleus and GMB-T317E has an open (an active) conformation in the cytoplasm.
This indicated that in living cells activation of MK2 and its nuclear export are coupled
by a phosphorylation-dependent conformational switch. (Neininger et al., 2001).
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Following phosphorylation of MK2, nuclear p38 is exported to the cytoplasm in a
complex with MK2. The cytoplasm translocation of MK2 requires phosphorylation by
p38 without a requirement for MK2 activity (Ben-Levy et al., 1998). MK2 serves both as
an effector substrate and as a determinant of cellular localization of p38. Nuclear export
of p38 and MK2 may permit them to phosphorylate cytoplasmic substrates, such as
eukaryotic initiation factor (eIE)-4E, PHAS-1 and Hsp25/27.
Since we could not measure the activation of MK5 in kinase assays even in the
transfected cells (Fig. 3-17), we further studied the subcellular localization of MK5 in
response to the stimulation of arsenite in transfected Hela cells try to find some cell
biological changes after stimulation. Hela cells were transfected with pEGFP-MK5 or co-
transfected with pEGFP-MK5 and pcDNA3-HA-p38 vectors. Transfected cells were
treated with or without SB203580 for 30 min, stimulated by 200 M arsenite. Export of
MK5 was analysed by fluorescence microscopy. It has been found that in the case of p38
co-transfected Hela cells, after stimulation by arsenite for 90 min, some MK5 export can
be found (Fig. 3-18). The export result corresponds with the kinase assay result, no export
(no activation) could be found in Hela cells only transfected with MK5-wt expression
vector even after 90 min. This further indicated that arsenite is not the suitable activator
of MK5.
pcDNA3-HA-p38   - -         +   +
pEGFP-MK5         + +         +   +
SB203580         + -         +   -




Fig. 3-18: Export of MK5
Hela cells were transfected with pEGFP-MK5 or co-transfected with pEGFP-MK5 and
pcDNA3-HA-p38 vectors. The transfected cells were treated with or without SB203580
for 30 min. The export of MK5 was analysed by fluorescence microscopy at 0, 60 and 90
min after stimulation by 200 M arsenite. Only in the case of p38 co-transfected Hela
cells, after stimulation by arsenite for 90 min, some MK5 export could be found. No
export of MK5 was found in other transfected cells.
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pcDNA3-HA-p38   - -         +   +
pEGFP-MK2         + +         +   +
SB203580         + -         +   -
Arsenite         + +         +   +
  0 min
30 min
60 min
Fig. 3-19: Export of MK2
Hela cells were transfected with pEGFP-MK2 or co-transfected with pEGFP-MK2 and
pcDNA3-HA-p38 vectors. The transfected cells were treated with or without SB203580
for 30 min. Export of MK2 was analysed by fluorescence microscopy at 0, 30 and 60 min
after stimulation by 200 M arsenite. The export of MK2 could be found after
stimulation by arsenite for 30 min and there were no difference on exporting between
pEGFP-MK2 transfected cell and the p38 co-transfected cells.
In order to compare MK5 with MK2, we also studied the subcellular localization of MK2
in the transfected Hela cells. Hela cells were also transfected with pEGFP-MK2 or co-
transfected with pEGFP-MK2 and pcDNA3-HA-p38 vectors. The export of MK2 could
be found after stimulation by arsenite for 30 min and there were no difference on
exporting between pEGFP-MK2 transfected cell and the p38 co-transfected cells (Fig. 3-
19). Compared with MK2, the export of MK5 was far from being complete and slower.
MK5 differs from MK2, with one regulatory phosphorylation site, T182. Like MK2,
MK5 also has a functional NLS and a NES. Prof. Ugo Moens and Dr. Ole Morten
Seternes analysed MK5 export. They found that “361RKRK364” of MK5 are involved in
the functional NLS and three “L” in “345LJVSLKPLHS354” motif are related to the
functional NES. Treatment of cells with arsenite results in nuclear export of MK5. Time
course studies showed that this transport was much slower then MK2. Sorbitol induced
nuclear export of MK2, but not of MK5. Arsenite-induced export of MK5 is inhibited by
leptomycin B (Prof. Ugo Moens and Dr. Ole Morten Seternes’ observation, submitted).
Our export results are comparable with theirs.
Both kinase assay and export results suggest that though there are some phylogentic
conservation between MK2 and MK5 (Fig. 3-1), MK5 is quite different from MK2
which is considered as the main direct downstream substrate of p38. Arsenite, sorbitol
which known as the activators of p38 MAPKs could not activate MK5 in our experi-
ments. It has been reported that PRAK, the human homologues of murine MK5, could
be activated by arsenite and PMA. (New et al, 1998). When we used the same antibody
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(this anti-PRAK provided by professor Jiahuai Han) to do the MK5 kinase assay, we
could detect the activation in wt MEF, but not in MK2 ko MEF (data not shown). This
indicated that this antibody was not specific enough and immunoprecipitated MK5 and
MK2 at the same time. Hence, the kinase activity measured in citated experiments was
probably due to a contamination of MK2 kinase activity. Since MK2 is much more
active toward this substrate than MK5, MK2 kinase activity could superimpose MK5
kinase activity.
Very recently, a new autoactivation pathway of p38a has been reported. It has been
found that p38a can be activated by autophosphorylation (Ge et al, 2002). This indicates
that there are some pathways of p38 MAPKs which are still unknown. In our MK5
kinase assay and export experiments, we could not activate MK5 kinase with some
activators already known for p38 MAPKs, there are two possibilities to explain this: (1)
p38-cascade had more alternative pathways and the activation conditions for p38
MAPKs to redirect the signal towards MK5 have not been found yet. (2) An alternative
possibility would be that MK5 is not or mainly not activated by p38 MAPK cascade in
vivo. Future work needs to be done to elucidate the mechanism of the activation of MK5
in vivo.
3. Analysis of MK5-Deficient Mice
MK2 ko mice show increased stress resistance and survive in LPS-induced endotoxic
shock which is due to a reduction of about 90% of TNF-a (Kotlyarov et al., 1999). To
analyse the MK5 deficient mice, therefore we firstly examined whether MK5 ko mice
response to LPS-induced endotoxic shock in the same way. Endotoxic shock was
induced by LPS and D-galactosamine. The mice were challenged with intraperitoneal
administration of 1 µg of LPS and 20 mg of D-galactosamine or 10 µg of LPS and 20
mg of D-galactosamine. In the lower dosage group, 8 of each genotype mice were
subjected to endotoxic shock. The first mouse died at 6 h after administration and each
genotype still had 5 survivors after 24 h (Fig. 3-20, a).
 (a)        (b)
Fig. 3-20: Effect of LPS/D-galatosamine on the survival in MK5 mutant mice
(a): Survival of wild type (+/+), MK5 (+/-) and MK5 (-/-) mice after treatment with
1 µg of LPS and 20 mg of D-galactosamine. (b): Survival of wild type (+/+), MK5 (+/-)
and MK5 (-/-) mice after treatment with 10 µg of LPS and 20 mg of D-galactosamine.
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In the higher dosage group, 8 MK5 +/+ and +/-, 9 MK5 -/- mice were subjected to the
endotoxic shock. The mice started to die after 4 h, two MK5 +/- and one MK5 -/- mice
still survived after 24 h (Fig. 3-20, b). There were no differences in surviving among the
three different MK5 genotype (+/+, +/- and -/-) mice respond to LPS-induced endotoxic
shock.
We further measured the production of the cytokines in spleen cells induced by LPS,
staphylococcal enterotoxin (SEB) or concanavalin A (Con A). The result is shown in
Fig. 3-21. We found that TNF-a production was not defective in MK5 ko mice, this
could explain why there were no differences in surviving among the three different
MK5 genotype mice in the LPS-induced endotoxic shock model. Production of IL-4 in
spleen cells stimulated by Con A seems to be defective in MK5 mutant mice in this
experiment, about 75% has been inhibited (P<0,05). The production of IL-12, both p40
and p70, shows a tendency to increased levels. Details are shown in Table 3-5.
    Fig. 3-21: Cytokines production by spleen cells
Spleen cells from wild type and MK5 ko mice were stimulated by LPS,
staphylococcal enterotoxin (SEB) or concanavalin A (Con A). The cytokines were
determined with an ELISA kit (QuantikineTM, R&D Systems).
p40 p70
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Table 3-4: Production of IL-4 and IL-12 of spleen cells derived from wt (+/+) and MK5 ko (-/-)
mice
        (a)             (b)
   Fig. 3-22: Leukocyte antigens
(a) Spleen cells from wild type and MK5 ko mice were examined with CD3, CD11,
CD19 and DX5 antigens. (b) T cells from wild type and MK5 ko mice were examined
with CD4 and CD8 antigens. wt: wild type mice; MK5 ko: MK5 ko mice.
Cytokines Mice and
Re
Sti. Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5 Average
LPS 32±4 12±11 30±17 0 0
SEB 780±244 57±21 139±50 43±4 7±422
wt
ConA 1000 307±55 423±101 418±70 42±124
LPS 24 15+-13 19+-11 0 0
SEB 32±7 39±14 99±23 84±9 129±34
Mk5 ko
ConA 101±6 78±19 101±16 121±39 185±24
LPS 75 125 63 87.7±26.8




ConA 10 25 24 21 44 24.8±10.0
LPS 22±027 416±12 18±134 877±375
SEB 170±21 289±11 301±51 816±290wt
ConA 172±15 126±13 146±29 71±4315
LPS 420±15 837+-82 262±44 1005±270
SEB 495±41 956±74 468±129 1270±133
Mk5 ko ConA 433±60 441±16 224±52 1275±494
LPS 191 201 145 115 163±34.8




(%) ConA 250 350 153 179 233±76.3
LPS 36 63±13 42±16
SEB 29 32±25 54±16wt
ConA 21 69±16 56±22
LPS 55±38 103±48 50±12
SEB 49±19 10±054 75±40
Mk5 ko ConA 54±21 94±38 72±15
LPS 150 163 118 143.7±18.9




(%) ConA 257 136 128 173.7±59
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Cytokine production also depends on the cell type. Therefore we checked the leukocyte
antigens and found that in MK5 ko mice, no significant change in the numbers of
monocytes/ marcrophages (CD11b), Pan T cells (CD3+), Pan B cells (CD19+), NK cells
(DX5), helper T cells (CD4+) and cytotoxic T cells (CD8+) was observed on analysis of
spleen cells and T cells (Fig. 3-22). This indicated that the differences among cytokine
production were not because of the differences of cell types and normal differentiation
and maturation of blood cells.
In human peripheral leukocytes and lymphoid organs, p38a mRNA expression is
relatively high, p38d expression is intermediate, and expression levels of p38ß and p38g
are low (Wang et al., 1997). p38 MAPKs may be involved in the production of various
cytokines at multiple levels of regulation. CD4+ Th cell responses can be divided into
distinct effector classes, Th1 or Th2, defined by the selective production of either IL-2
and IFN-g, which primarily promote cell-mediated immunity (Th1), or IL-4 and IL-5,
which promote IgE production and eosinophilia (Th2) (Constant & Bottomly, 1997). Of
these two classes, the development of the Th2 response is especially dependent on CD28
costimulation. In several studies, human CD4+ T cells stimulated in vitro without CD28
costimulation developed a Th1 phenotype, producing only IL-2 and IFN-g, whereas the
addition of an anti-CD28 Ab to the culture converted the population to a Th2 phenotype,
inducing production of IL-4 and IL-5. (King et al., 1995; Webb and Feldmann, 1995;
Kalinski et al., 1995). It has been shown that CD28 ko mice exhibited greatly reduced
IL-4, IgE, and IgG1 production in response to anti-IgD Abs (Gause et al., 1997), this
indicated that particular Th2 responses may vary in their dependence on CD28. For
MK5 ko mice, further work with CD28 costimulation needs to be done and in this way,
maybe we can find some activators of MK5.
It has been also reported that the production of IL-5, IL-6, IL-9, IL-10 and IL-13 are
impaired in IL-4 ko mice because IL-4 is required for the generation of Th2-derived
cytokines, and therefore, immune responses dependent on these cytokines become
impaired (Kopf et al., 1993; Kopf et al., 1995). In MK5 ko mice, the release of IL-10
was not affected (Fig. 3-21; Table 3-5). Future work might identify whether MK5 ko
mice are defective on production of some other Th2-derived cytokines. It has been
demonstrated that the p38 MAPK pathway is necessary for IFN-g production by Th1
effector T cells without affecting IL-4 production by Th2 cells (Rincon et al., 1998). In
both Th1 and Th2 cells, CD28 signalling activated p38 and was required for cytokine
production. In polarized Th1 and Th2 cell lines, SB 203580 strongly inhibited IL-4
production by Th2 cells, but only partially inhibited IFN-g and IL-2 production by Th1
cells (Schafer et al., 1999). MK2 ko mice show markedly defective on production of
TNF-a and IFN-g (Kotlyarov, 1999) while MK5 ko mice are defective on production of
IL-4. This indicated that MK2 ko mice are defective on Th1 effector T cells whereas
MK5 ko mice are maybe defective on Th2 effector T cells. MK2 and MK5 may stand
different functions on cytokines production in p38 MAPK pathway. Future studies using
the MK2 and MK5 double ko mice, we can make further demonstration of the Th
effector T cells. Therefore, the functions of MK2 and MK5 on cytokine production are
different. By this means, MK5 maybe also serve as a promising target for specific anti-
inflammatory therapy.
Germinal centers (GCs) are known as compartments for B cell differentiation and
proliferation. After stimulation of antigen (Ag), GC B cells differentiate into memory
cells or plasma cell precursors (Liu et al., 1996). Production of plasma cell precursors and
maintenance of serum Ab levels are closely related to GC function (Wu et al.,
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      wt              MK5 ko
Fig. 3-23: Germinal centre formation in spleens of wt and MK5 ko mice after
immunization for 12 days.
After immunization with human serum albumin coupled to DNP in incomplete Freunds
adjuvant (IFA) for 12 days, the mice were killed and the germinal centres in the spleen
were examined. The centrocytes (red) were stained by rhodamine-labelled peanut
agglutinin (PNA) and the B-cells (green) were co-stained by FITC-B220-pan-B. wt: wild
type mice; MK5 ko; MK5 ko mice.
1996). Therefore, the kinetics of GC size and number should be closely related to the
magnitude and characteristics of humoral immune response. Our observation revealed
that after immunization, the mice were able to form germinal centres, but the germinal
centres in MK5 ko mice were significantly enlarged (Fig. 3-23). Furthermore, the Ab
production in wt and MK2 ko mice was increased after secondary Ag challenge, but in
MK5 ko mice this production was unchanged (Fig. 3-24). Similar result of the abnormal
germinal center formation was reported to be found also in IL-4 ko mice.  In comparison
with wt mice, lymph nodes (LNs) of IL-4 ko mice on days 4 and 7 after final Ag
challenge were larger and contained a markedly greater number of GCs, which showed
marked size variations with a large number of small GCs and a small number of markedly
large GCs. By day 14, the number of GCs decreased to the same level as that in wt mice.
However, the LN size in IL-4 ko mice was still larger than that in wt mice due to the
presence of markedly large GCs (Andoh et al., 2000). It has been also reported that the
complete absence of GC formation in Peyer’s patches of IL-4 ko mice after oral
immunization (Vajdy et al., 1995).
IL-4 is very important in GC B cell differentiation (Cerutti et al., 1998) and in B cell-
FDC (Follicular dendritic cell) interaction (Tew et al., 1997). IL-4 production is defective
in MK5 ko mice which may result in, at least partly, the abnormal germinal center
formation. The same abnormal germinal center formation was also found in MK2 ko mice
and which is probably due to the decreased apoptosis of cells in germinal center
(Kotlyarov, 1999). This indicates that MK2 and MK5 may share an overlapping function
or have a common downstream substrate on transducing apoptosis signal in p38 MAPK
cascades.




Fig. 3-24: Production of immunoglobulins after immunization
Sex-matched animals, 6-12 weeks old, were immunized by intraperitoneal
administration of 100 mg of human serum albumin coupled to DNP in incomplete
Freunds adjuvant (IFA). Serum samples were collected from the mice10 days after
primary immunization (a) or secondary immunization (b). Levels of DNP-specific
immunoglobulin (Ig) isotype were determined by ELISA (Southern Biotechnology
Associates). Anti-mouse Ig capture antibodies were used for the measurement of
non-specific antibodies level. c: control; mk2: MK2 ko mice; mk5: MK5 ko mice.
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4. Further Analysis of MK5-Deficient Mice
Although MK5/PRAK was found three years ago, we still know very less about this
kinase. To study the role of the p38 MAPK pathway, and the function of MK5 in vivo,
we have generated mice with a germline mutation of the MK5 gene. The mice have been
characterised by Southern blot analysis, RT-PCR, sequencing, Western blot analysis and
protein kinase assays which all demonstrated that the targeted disruption of the MK5
gene resulted in a null allele.
MK5-deficient mice were viable and fertile. The intrinsic MK5 kinase activity is absent
in MK5 deficient mice and could be detected in wt mice, but we were not able to
activate this kinase with typical p38 pathway stimuli in our experiments. The further
analysis of MK5 deficient mice would be firstly to find the proper activator of this
kinase and to elucidate the signal transducing pathway of MK5. It is also very important
to find the biological relevant substrates of MK5 and to demonstrate if Hsp25/27 is a
substrate of MK5 in vivo.
Analysis of cytokine production revealed a defect in the production of IL-4 in spleen
cells stimulated by Con A in MK5 mutant mice in our experiment. The production of
IL-12, both p40 and p70, shows a tendency to increased levels. The defect of MK5
deficient mice in the production of IL-4, could result in an impaired Th2 CD4+ immune
response. Future work might identify that if MK5 ko mice are also defective on
production of some other Th2-derived cytokines. It would be also interesting to know
whether the regulatory mechanism involves the transcriptional or post-transcriptional
processes.
p38 MAPK cascade regulates gene expression, correlates with apoptosis and controls
cell growth and differentiation. With MK2 ko mice, MK5 ko mice and double ko mice
(both MK2 and MK5), we would be able to identify the specific functions of MK5 and
demonstrate if MK5 plays a role on inflammatory response, apoptosis or cell division.
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